


Nutrients, Diet and Lifestyle: Reframing Chronic Kidney Disease as a Systems Disorder

Michael Osiecki

PhD, BE(chemical), BBiotech (Hons.)





Conflict of Interest


- Dr. Michael Osiecki is the Managing Director and owner of Bio Concepts which sells Nutraceuticals under the brand of Orthoplex.
- Dr. Michael Osiecki is the Vice Chair of Complementary Medicines Australia (CMA), a peak industry body that represents Manufacturers, Sponsors, Suppliers, Retailers and Practitioners in the complementary medicine industry.

Outline

- The renal problem and how to identify at risk patients.
- Renal disease as a cause and driver of comorbid conditions
- Exploring Malnutrition and Protein
- Further supplemental support

Global Prevalence



Globally CKD has a prevalence of 7.2% for >30 years of age, rising to 23.4-35.8% for those older than 64 years



Mark, P. B., Stafford, L. K., Grams, et. El J. (2025). The Lancet, 406(10518), 2461–2482. [https://doi.org/10.1016/S0140-6736\(25\)01853-7](https://doi.org/10.1016/S0140-6736(25)01853-7)

Tungsanga, S., Okpechi, I. G., Bianchi, M. E. V., Chaturvedi, S., Collister, D., Crowshoe, H., ... Bello, A. K. (2026). Nature Reviews Nephrology, 22(2), 99–121. <https://doi.org/10.1038/s41581-025-01016-2>

The Silent Disease is on the Rise



Australian Institute of Health and Welfare. Chronic Kidney Disease: Australian Facts. Aust Gov. 2023;(February):1-121.

Mark, P. B., Stafford, L. K., Grams, et. El J. (2025). The Lancet, 406(10518), 2461–2482.

[https://doi.org/10.1016/S0140-6736\(25\)01853-7](https://doi.org/10.1016/S0140-6736(25)01853-7)

Chronic kidney disease. (n.d.). NHS England Digital. Retrieved September 17, 2025, from

<https://digital.nhs.uk/data-and-information/publications/statistical/health-survey-for-england/2022-part-2/kidney-disease>

Liyanage T, Toyama T, Hockham C, et al. BMJ Glob Heal. 2022;7(1):1-9. doi:10.1136/bmjgh-2021-007525

Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., Callaghan, A. O., Lasserson, D. S., & Hobbs, F. D. R.

(2016). PLoS ONE, 11(7), 1–18.

Lee, W., Lee, Y., Li, L., Ng, H., Kuo, W., Lin, P., Liao, Y., Chiou, T. T., & Lee, C. (2018)Journal of Clinical Medicine, 12(7), 493. <https://doi.org/10.3390/jcm7120493>

Cerda, J., Kashani, K., Ostermann, M., Basu, R. K., et al. (2026). Nature Reviews Nephrology, 22(3), 179–198. <https://doi.org/10.1038/s41581-025-01030-4>

Chronic Kidney Disease (CKD)



Increased risk of all forms of death and higher susceptibility to other disease conditions:

- **Cardiovascular disease, at least double that of the general population and major cause of death**
- **Diabetes**
- Cancer
- Infections
- Stroke
- Sarcopenia
- Dementia

Integrative medicine considerations:

- Malnutrition; 40% CKD population is malnourished: Vitamin, mineral (imbalance) and amino acid deficiency (protein wasting) and metabolism (vitamin D)
- **Anaemia**
- **Metabolic acidosis**
- **Secondary hyperparathyroidism (vitamin D3 deficiency, hyperphosphataemia, hypocalcaemia)**
- Increase of ROS and inflammation
- Intestinal hyperpermeability and gut dysbiosis
- AGE and increase RAGE
- NAFLD
- Adipokines and leptin resistance
- Mitochondrial dysfunction (fatigue)
- Arthritis.

CKD is a Systematic Inflammatory Disease



Pathology Analytes



Diagnostic Criteria

- Diagnosed by blood: Urea, Creatinine and albumin, GFR/eGFR, proteinuria
- imaging or biopsy.

Further Considerations

Markers are in the range or trending outside the ranges.



- eGFR – calculated with creatinine or cystatin C. Values between 60 and 90 ml/min/1.75 m² need to be investigated with urinalysis. Rate of decline is important here.
- eGFR based on creatinine overestimates function, especially >60 ml/min/1.75 m²

- Difference between eGFR (Cys C) – eGFR (Creat) (diff<-10) has a higher mortality and renal failure.
- Cystatin C- reciprocal (1/Cys C) may be more sensitive to renal decline than creatinine levels (0.5-1 mg/L)
- Bicarbonate – low (22-29 umol/L)
- Anion Gap – high (8-16 mmol/L)
- Urea – high (2.5-7.8 mmol/L)
- Creatinine – high (M: 59-104 umol/L, W: 45-84 umol/L)
- Uric acid/urate – high (M: 0.2-0.45 mmol/L, F: 0.15-0.4 mmol/L)
- Phosphate and potassium
- Low/decreasing lymphocytes




Zoccali, C., Vanholder, R., Massy, Z. A., Ortiz, A., Sarafidis (2017). Nature Reviews Nephrology, 13(6), 344–358. <https://doi.org/10.1038/nrneph.2017.52>
Potok, O. A., Katz, R., Bansal, N., Langlo, K. A., & Hallan, S. I. (2026). Kidney Medicine, 8(1). <https://doi.org/10.1016/j.xkme.2025.101129>
Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., Callaghan, A. O., Lasserson, D. S., & Hobbs, F. D. R. (2016). PLoS ONE, 11(7), 1–18.
Miwa, K., Tanaka, M., Okazaki, S., Furukado, S., Yagita, Y., Sakaguchi, M., Mochizuki, H., & Kitagawa, K. (2014). Neurology, 82(12), 1051–1057.
Lee, W., Lee, Y., Li, L., Ng, H., Kuo, W., Lin, P., Liao, Y., Chiou, T. T., & Lee, C. (2018) Journal of Clinical Me,

12(7), 493. <https://doi.org/10.3390/jcm7120493>
Yuen, N. K., Ananthakrishnan, S., & Campbell, M. J. (2016). The Permanente Journal, 20(3), 78–83. <https://doi.org/10.7812/TPP/15-127>
Dharmidharka, V. R., Kwon, C., & Stevens, G. (2002). American Journal of Kidney Diseases, 40(2), 221–226. <https://doi.org/10.1053/ajkd.2002.34487>
Bergström J. J Am Soc Nephrol. 1995;6(5). https://journals.lww.com/jasn/Fulltext/1995/11000/Nutrition_and_mortality_in_hemodialysis.2.aspx

Stages of Renal Failure and Comorbidities and Contraindications






eGFR and Age




eGFR Rate of Decline - Key Diagnostic

- Not everyone with CKD will progress to end stage renal disease. However, patients who have a drop of >3 ml/min/1.73 m²/year are extremely likely to be on dialysis within 10 years.
- Healthy people on average lose 0.4 ml/min/1.73m²/year.
- Patients with this rate of decline are a priority for intervention.





CKD and Anaemia

- Erythropoietin is mostly made in the kidney. When damaged, the production decreases.
- Along with a loss of protein and iron, red blood cell production decreases.
- Elevated urea & uraemic toxins (indoxyl sulfate and p-cresyl sulphate) inhibit EPO signalling & is a bigger driver of anaemia.
- Inflammation induces hepcidin, reducing circulating free iron and hypoferraemia. Inducing degradation of ferroportin in the enterocytes.
- Anaemia is a major driver of renal disease progression due to subsequent hypoxia in all organs. Therefore, a feedforward process of further damaging the kidneys and leading to heart failure.



Renal Function Correlates with Haemoglobin and EPO Levels



Endocrine Disruption in Renal disease

The etiology of selected endocrine abnormalities in chronic kidney disease

Type of defect	Example
Abnormalities of hormone catabolism	
Decreased metabolic clearance	Insulin, PTH, leptin, adiponectin, gastrin
Abnormalities of hormone production	
Reduced hormone production in endocrine organs	testosterone, estrogens
Reduced hormone production by the kidney	1,25(OH) ₂ D ₃ , erythropoietin
Reactive hypersecretion of hormone to reestablish homeostasis	PTH, FGF 23, erythropoietin
Inappropriate hypersecretion due to disturbed feedback	ACTH, LH, prolactin
Abnormal secretion pattern (pulsatility; circadian rhythm)	GH, LH
Abnormalities of hormone activity	
Increased isoforms with potentially less bioactivity (because of posttranscriptional modifications)	LH
Increased serum hormone binding proteins concentration resulting in the reduced availability of free hormone	IGF
Decreased serum hormone binding proteins concentration resulting in the increased availability of free hormone	leptin
Changed receptor quantity and/or structure	vitamin D receptor
Altered postreceptor cellular signaling	insulin, GH
Altered activation of prohormones	proinsulin, thyroxin (T ₄)

Hypothalamic-pituitary-gonadal axis disturbances in chronic kidney disease



	Female	Male
FSH	N	↑
LH	↑	↑
Prolactin	↑	↑
Estradiol	↓	N
Progesterone	↓	—
Testosterone	—	↓

Hypothalamic-pituitary-thyroid axis alterations in chronic kidney disease, chronic nonthyroidal, nonkidney illness and primary hypothyroidism



	TSH	T ₄	T ₃	rT ₃
Chronic kidney disease	N	N, ↓	↓	N
Chronic nonthyroidal, nonkidney illness	N	N, ↓	↓	↑
Primary hypothyroidism	↑	↓	↓	N

Menopause: An Initiator of Renal Function Decline


- The hormonal changes in menopause result in increased prevalence of hypertension, diabetes and dyslipidaemia that increases the risk of cardiovascular disease and CKD.
- The changes in mineral balance of calcium (bone loss) and increasing sensitivity to sodium due to the drop in oestrogen puts pressure on the kidneys.
- Oestrogen decreases angiotensin 1 receptors in the kidney (vasoconstriction pathway), as well as ACE and increases AGT.
- Poor sleep compounds the effects
- We see renal function decline in at-risk women at menopausal age.



How CKD or AKI Damages the Central Nervous System



Uremic Toxins: The Gut Kidney Axis



Renal disease leads to a build-up of uremic toxins, driving inflammation which feeds back to gut dysbiosis and disrupting protein post translational modifications

The Gut-Kidney Axis

- CKD results in disruption to the intestinal barrier as well as changes to the microbiome. Through influx of circulating urea to the gut lumen and dietary restriction that reduces food containing fibre to avoid hyperkalaemia and hyperphosphataemia.
- These factors promote systemic inflammation and cardiovascular morbidity by mediating microbial dysbiosis, disruption of the intestinal epithelial barrier, and translocation of endotoxin, bacterial fragments, and uraemic toxins across the “leaky gut” into the bloodstream.
- This can lead to further immunosuppression.
- Uraemic toxins and gut issues cause disruption in nutrient absorption and microbiome production of vitamins like thiamine leading to functional deficiencies.
- Constipation is common in CKD patients and can increase the production of uraemic toxins like p-cresyl sulphate.
- Low protein diets can alter the microbiome and reduce uraemic toxin production.
- Prebiotics can reduce serum urea -2.23 mmol/L, 95% CI -3.83 to -0.64 , $P = 0.006$.


Dialysis treatment for one year has a 10-15% mortality rate

5-year survival rate of 40-50%

Can drop further with co-morbid conditions like diabetes and CVD, 5-year survival rate is 25%

Highest risk is in the first 3 months

While transplant survival is 80% after 5 years



**CKD is a
disease of
malnutrition**



Sarcopenia and CKD

- Prevalence of sarcopenia in CKD patients 9-65% higher than age matched populations. This is more on the higher side when the patient is on dialysis at 25-75%.
- Older (>75 years) patients on dialysis have a far higher rate of sarcopenia than less senior (65-74 years) patients, 55% v 12.5%.
- Muscle degradation is more of a factor in CKD, with higher levels of inflammation, insulin resistance, metabolic acidosis, vitamin D deficiency and oxidative stress.
- Overall malnutrition leads to higher mortality for CKD patients.

	CKD-related sarcopenia	Ageing-related sarcopenia
Muscle protein degradation	Increased	No change/increased
Muscle protein synthesis	Decreased	Decreased
Resting energy expenditure	Increased/unchanged	Unchanged
Inflammation	Increased	Increased or unchanged
Insulin resistance	Present	Present
Body fat	Unchanged, increased or decreased	Normally increased
Muscle fiber change	Atrophy in type I and II fibers	Preferential loss of type II fibers

Kidney and Amino Acid Metabolism

The kidney and amino acid metabolism

UPTAKE (% of body disposal)

Glutamine	30%
Proline	60%
Citrulline	100%
SAH	100%
Cysteinyl-glycine	90%







RELEASE (% of body release)

Serine	100%
Cysteine	100%
Arginine	50%
Tyrosine	50%
Lysine	5-20%

Amino acids filtered and reabsorbed: ~300 mmol/day

Malnutrition in Acute Kidney Injury



Amino Acid Metabolomic Profiling between CKD and ESKD

Table 2. Plasma concentrations of amino acids and amines in nondialyzed patients with CKD stages 2–5 and hemodialyzed patients (micromoles per liter)

Variables	CKD2–5 (n=52)	Hemodialysis (n=25)	P Value
Total amino acid	2558.3±441.7	2162.9±615.4	0.01 ^a
Total essential amino acid	989.8±237.9	762.1±284.0	<0.001 ^a
Total nonessential amino acid	1568.5±272.4	1400.8±379.8	0.06
Total branched chain amino acid	405.4±138.1	314.7±127.2	0.01 ^a
Alanine	320.9±102.8	232.7±90.4	<0.001 ^a
Arginine	91.0±29.9	68.0±29.6	<0.001 ^a
Asparagine	40.9±10.0	40.5±14.6	0.58
Aspartate	5.8±19.5	15.7±23.1	0.01 ^a
Citrulline	49.9±24.2	67.5±26.1	0.01 ^a
Glutamine	526.6±70.3	473.2±117.8	0.04 ^a
Glutamate	84.9±83.4	58.3±49.0	0.09
Glycine	187.6±62.2	166.8±54.0	0.27
Histidine	76.4±14.9	67.8±25.6	0.03 ^a
Isoleucine	75.9±28.6	61.5±25.4	0.03 ^a
Leucine	114.0±50.0	87.3±47.6	0.02 ^a
Lysine	189.6±45.1	150.3±62.9	0.001 ^a
Methionine	37.5±11.4	26.8±12.0	<0.001 ^a
Ornithine	60.9±22.9	56.1±19.3	0.39
Phenylalanine	67.0±15.8	59.2±18.0	0.06
Proline	228.9±70.5	279.7±108.7	0.04 ^a
Serine	82.0±19.3	65.9±27.6	0.003 ^a
Threonine	100.6±29.9	75.8±36.5	0.01 ^a
Tryptophan	48.4±14.4	24.0±14.1	<0.001 ^a
Tyrosine	65.0±22.7	43.5±17.8	<0.001 ^a
Valine	215.4±69.0	165.9±62.1	0.003 ^a
Asymmetric dimethylarginine	0.81±0.4	1.79±0.6	<0.001 ^a
Symmetric dimethylarginine	1.17±2.4	0.64±0.4	0.03 ^a
Hydroxykynurenine	2.07±1.2	5.50±1.8	<0.001 ^a

All values are mean ± SD.

^aP<0.05.

Table 3. Plasma concentrations (micromoles per liter) and urinary excretion (micromoles per mole creatinine) of amino acids and amines in nondialyzed CKD patients

Variables	Plasma Concentration			Urinary Excretion		
	CKD2–3	CKD4–5	P Value	CKD2–3	CKD4–5	P Value
Total AA	2512.4±411.0	2597.7±470.2	0.49	246.5±107.1	324.8±303.2	0.90
Total essential AA	1006.0±234.1	975.9±244.5	0.68	71.8±35.4	104.7±101.4	0.80
Total nonessential AA	1506.4±249.4	1621.8±284.4	0.13	200.1±126.8	220.1±204.5	0.56
Total branched chain AA	421.4±133.5	391.6±142.9	0.41	6.1±7.2	7.1±15.8	0.18
Alanine	305.3±100.0	334.3±105.0	0.32	23.8±21.5	30.7±29.2	0.54
Arginine	88.5±25.7	93.1±33.3	0.58	7.8±6.6	8.2±6.0	0.42
Asparagine	38.6±10.4	43.0±9.2	0.11	7.2±3.3	14.7±14.7	0.07
Aspartate	6.1±23.4	5.6±15.9	0.56	12.7±15.0	9.0±22.4	0.08
Citrulline	35.9±16.3	61.8±23.6	<0.001 ^a	1.0±1.2	7.1±14.3	<0.001 ^a
Glutamine	514.8±68.3	536.6±71.6	0.27	25.0±15.8	31.4±44.2	0.40
Glutamate	72.1±45.3	96.0±105.4	0.83	29.8±61.5	19.3±25.1	0.50
Glycine	185.3±48.1	189.5±73.1	0.71	69.9±44.8	67.6±69.6	0.32
Histidine	74.9±11.2	77.7±17.5	0.61	34.9±23.4	30.0±26.0	0.30
Isoleucine	76.7±26.9	75.2±30.4	0.80	0.9±1.9	0.6±2.9	0.11
Leucine	124.8±45.1	104.9±53.0	0.12	2.2±3.5	2.2±5.9	0.23
Lysine	186.3±45.7	192.4±45.2	0.53	10.4±10.3	26.5±30.7	0.11
Methionine	36.6±11.8	38.3±11.2	0.59	1.2±1.1	1.3±1.9	0.50
Ornithine	53.9±22.6	66.9±21.8	0.01 ^a	15.4±57.1	1.8±5.1	0.33
Phenylalanine	62.9±12.0	70.5±17.9	0.15	4.9±2.9	6.7±7.1	0.94
Proline	212.4±71.8	243.0±67.5	0.12	2.6±2.6	13.8±18.5	<0.001 ^a
Serine	83.4±20.7	80.7±18.1	0.62	21.3±10.2	25.4±19.7	0.73
Threonine	101.6±31.9	99.8±28.6	0.92	11.1±10.5	20.9±29.1	0.43
Tryptophan	55.5±12.3	42.3±13.4	<0.001 ^a	4.5±2.5	4.8±3.9	0.88
Tyrosine	66.9±22.8	63.3±22.9	0.59	6.5±3.9	7.5±6.9	0.94
Valine	219.9±64.6	211.6±73.6	0.69	3.0±2.6	4.3±7.9	0.54
ADMA	0.57±0.29	1.02±0.48	<0.001 ^a	2.37±0.93	1.51±1.43	<0.001 ^a
SDMA	1.54±3.48	0.85±0.58	0.69	2.85±0.93	2.89±2.91	0.06
Hydroxykynurenine	1.19±0.39	2.82±1.22	<0.001 ^a	0.13±0.10	0.45±0.90	0.15

All values are mean ± SD. CKD2–3, CKD stages 2 and 3; CKD4–5, CKD stages 4 and 5; AA, amino acid; ADMA, asymmetric dimethylarginine; SDMA, symmetric dimethylarginine.



^aP<0.05.

Durant F, Lundin U, Gayraud N, et al. *Clin J Am Soc Nephrol*. 2014;9(1):37–45. doi:10.2215/CJN.06000613

Zobel EH, von Scholten BJ, Reinhard H, et al. *Cardiovasc Diabetol*. 2017;16(1):1–9. doi:10.1186/s12933-017-0569-8

Garibotto Giacomo G, Sofia A, Saffioti S, Bonanni A, Mannucci I, Verzola D. *Clin Nutr*. 2010;29(4):424–433. doi:10.1016/j.clnu.2010.02.005


Citrulline/Arginine: It's Complicated




- Citrulline in early stage or non-CKD patients is better at increasing serum arginine levels and NO levels.
- Supplementation is indicated for diabetic nephropathy and hyperfiltration. Protection against endothelial dysfunction.
- Polyphenols, ECCG and anthocyanins increase the surface expression of eNOS and decrease ADMA.

What is the go with Creatine?

- The kidney is a mitochondrial dense organ, it needs energy for maintaining membrane potential and reuptake of key metabolites and nutrients in the urine.
- Creatine phosphate is needed throughout the body cell types as an intermediary to transport ATP from the mitochondria throughout the cytosol.
- The first step in the metabolism of creatine using glycine and arginine occurs in the kidney.
- Creatine deficiency is highly prevalent in renal patients.
- **Neither creatine supplementation nor its metabolite creatinine causes renal damage.** Creatinine is used as a marker. Most studies show creatine supplementation has no significant effect on creatinine levels.
- From 2-5g daily doses, it is recommended to cease supplementation two weeks before diagnostic tests.
- Creatine synthesis can pull 40-70% on the SAME pool. Supplemental creatine helps the stores of methyl donors therefore methylation as a whole.



Creatine Essential to Support CKD Patients



Histidine: The Forgotten Essential Amino Acid




Antioxidant

- Scavenger of reactive oxygen (ROS) and reactive nitrogen (RNS) species & hydroxyl radicals. Mediated by metal ion chelation.
- Sequestering advanced glycation and advanced lipid oxidation end products often related to complications in renal disease, microangiopathy and retinopathy in diabetes



Anti-inflammatory

- The antioxidant effects are associated with the inhibition and regulation of proinflammatory biomarkers IL-6, CRP and TNF- α , particularly in chronic disease states.
- Combines with beta alanine to make carnosine.



Dosage range
2-6 g/day



Ph buffer

- Of all the amino acid side chains in proteins, only the imidazole ring of HIS functions as a pH buffer – acting as an acid or a base as required.
- It can attenuate changes in intracellular pH in muscles during anaerobic exercise (reducing muscle fatigue) and has even been used in solutions to preserve organs for transplantation



Metal ion chelation & detoxification

- The structure of HIS contains an imidazole ring which allows the efficient chelation with divalent metal ions Fe²⁺, Cu²⁺, Co²⁺, Ni²⁺, Cd²⁺ and Zn²⁺, filling the gaps of N-acetylcysteine's thiol group chelation of Fe³⁺, Pb²⁺ and Hg²⁺.
- Moderate doses (2-6g daily) of HIS protect against the negative effects of free-floating metal ions and takes them to where they are needed.
- In higher doses (>10g daily) HIS has also been shown to protect against copper-induced neurotoxicity.


Histidine: Clinical Effects

- Combines with beta alanine to make carnosine.
- Key for protein function e.g. metalloproteins, albumin and histidine rich glycoproteins.
- Histidine is essential in globin synthesis and erythropoiesis. Histidine deficiency leads to anaemia. Even in chronic uraemic patients. Used with EPO, **~700mg/day** histidine maintained haemoglobin at a higher level after week 12 and week 24.
- Alternate methylation pathway. Through the conversion to N-formimino-L-glutamate and using formimidoyltransferase-cyclodeaminase enzyme acts as a methyl-donor to THF to MTHF.
- Helps iron uptake in the GI and prevents free iron damage in iron infusion in renal patients when co-supplemented.
- Low plasma concentrations are associated with protein-energy wasting, inflammation, oxidative stress, and greater mortality in CKD patients.

Histidine: Clinical Effects

- Epidemiological/observational studies and a few small clinical trials show histidine is effective at decreasing BMI, adiposity & metabolic markers (fasting glucose, postprandial blood glucose).
- A clinical trial of **4g/day for 12 weeks** showed increased insulin sensitivity and decreased fasting glucose by reduced gluconeogenesis in the liver via the histamine 1 receptor. Also reduced appetite.
- Another clinical trial of **2g/day for 2 weeks** showed less fatigue, improved sleep, mental focus, peripheral blood flow and anxiety.
- Improves libido, through histaminergic system in the brain to increase arousal of the forebrain and vasodilation and blood flow in peripheral sexual tissue.
- **4g/day for 4 weeks** reduces atopic dermatitis severity by 39%, by increasing filaggrin.


Low Protein Diet - What is the True Evidence?



Able to delay progression to ESRD (dialysis). However, diet was unable to reduce the eGFR decline.

High Protein? Keto? Not all Protein is Equal

- Keto with a high fat content may be beneficial in CKD.
- Emerging evidence that Keto diet is better suited for polycystic renal disease.
- Patients on Keto diet run the risk of acidosis if not taking a strong plant approach.
- Better on a plant base protein; low carbohydrate (5-45%) and supplementing with mineral citrates.
- Safer in patients in stage 2-3 CKD. Oddly showed no benefit in CKD with T2D.
- Ultimately haven't shown superiority over other diets and have a higher risk factor.



Athinarayanan, S. J., Roberts, C. G. P., Vangala, C., Shetty, G. K., McKenzie, A. L., Weimbs, T., & Volek, J. S. (2024). *BMJ Open Diabetes Research & Care*, 12(2). <https://doi.org/10.1136/bmjdr-2024-004101>

Torres JA, Kruger SL, Broderick C, et al. *Cell Metab*. 2019;30(6):1007-1023.e5. doi:10.1016/j.cmet.2019.09.012

D'Alessandro, C., Giannese, D., Piccoli, G. B., Panichi, V., & Cupisti, A. (2025). *Journal of Nephrology*, 38(6), 1541–1556. <https://doi.org/10.1007/s40620-025-02285-7>

Mitch WE, Remuzzi G. *BMC Nephrol*. 2016;17(1):1-8. doi:10.1186/s12882-016-0283-x

Crosby L, Davis B, Joshi S, et al. *Front Nutr*. 2021;8(July):1-11. doi:10.3389/fnut.2021.702802

Ong ACM, Torra R. *Clin Kidney J*. 2022;15(6):1034-1036. doi:10.1093/ckj/sfac103

Joshi, S., Shi, R., & Patel, J. (2024). *Clinical Kidney Journal*, 17(1), sfad274. <https://doi.org/10.1093/ckj/sfad274>

High Protein? Keto? Not all Protein are Equal


- High protein diets often lead to hyperfiltration. Through neuronal NO synthase β in the macula densa via tubuloglomerular feedback.
- Hyperfiltration is associated with rapid decline of renal function.
- Relative risk of hyperfiltration is 3.48 times higher in the highest protein intake population compared to the lowest in the general population.
- Low carbohydrate and high protein diet in healthy subjects increases acid load, increases the risk of stone formation, decreases estimated calcium balance, and may increase the risk for bone loss.
- Plant based diet that has a low inflammatory index is the most beneficial with normal protein levels. Mushrooms are very useful due to complete amino acid profile, vitamin mix, low acid load, low phosphorous and ergothioneine content.

A Diet is Better Than None at All

- Two-year randomised trial comparing low-carbohydrate (non-restrictive, 22% energy protein) to Mediterranean (calorie restriction, 19% energy protein) and low-fat (calorie restricted, 19% energy protein).
- Improvements in eGFR were achieved in low-carbohydrate (+5.3% [95% CI 2.1–8.5]), Mediterranean (+5.2% [3.0–7.4]), and low-fat diets (+4.0% [0.9–7.1]) with similar magnitude ($P > 0.05$) across diet groups.
- Dietary adherence is key. Adherence American Heart Association (AHA) dietary pattern was significantly associated with the lowest risk of developing CKD (HR=0.63, 95% CI 0.55-0.71, Q5 vs. Q1). In comparison, adherence to other dietary patterns such as the Diabetes Risk Reduction Diet (DRRD) and EAT-Lancet diets conferred weaker protective associations. Conversely, the high adherence to an unhealthful Plant-Based Diet Index (PDI) was linked to an elevated CKD risk (HR = 1.44, 95% CI: 1.26-1.64, Q5 vs. Q1).
- Animal protein higher in sulphuric amino acids (cysteine, methionine) is associated with acidosis and risk of ESRD. Simply changing from red meat to white reduces risk.
- The urea/uric acid from protein metabolism is always going to be an issue. Serum uric acid is associated with renal disease progression.

Potassium

- Na/K ratio needs to be controlled.
- Potassium is important for cardiac function and to counteract the effect of excess sodium. Also helps in buffering.
- CKD results in abnormal potassium metabolism. Excretion drops in chronic renal failure.
- Can lead to hyperkalaemia during acidosis, especially high risk at stage 4/5 and dialysis patients.
- Patient specific sensitivity either retaining or removing potassium during dialysis.
- Target range for CKD patients is 4-5.4 mmol/L. May want to have tighter bounds as renal function declines.
- RDI M: 3400 mg, F: 2600 mg is the safe intake for stages 1 and 2.
- For stage 3 and below best to limit potassium to 2000 mg/day and for stage 4&5 1500 mg/day
- Haemodialysis can go up 2000 mg/day, peritoneal dialysis 2000-2500 mg/day
- Hyperkalaemia risk comes from supplementation, salt substitutes and medication (RAAS inhibitors and MRAs) more than dietary. However, SGLT2 inhibitors and GLP-1 agonists reduce this risk, which now allows more flexibility.



Hoorn, E. J., Subramanya, A. R., & Boyd-Shiarski, C. R. (2026). *Nature Reviews Nephrology*, 1–16. <https://doi.org/10.1038/s41581-026-01053-5>
Yamada, S., & Inaba, M. (2021). *Nutrients*, 13(6), 1–19. <https://doi.org/10.3390/nu13061751>

Nutrients for Mitochondrial Support & Oxidative Stress

- Mitochondria dysfunction is a hallmark in kidney disease; detected by urinary lactate levels.
- CKD associated with deficiency in oxidative defence systems. Vitamins C, D and E are essential along with selenium and B vitamins.
- Mitochondrial support is very important: CoQ10 (any form, 300 mg+), L- & acetyl-L-Carnitine (1 g), lipoic acid (50-300+ mg), B3/NAD producers, creatine (5g).
- Taurine, NAC and histidine can sequester selected non-radical oxidants.
- Taurine is deficient in tissues of CKD patients; low in dialysis patients.
- Taurine can accumulate in tissue quickly at higher dosages, keep below 4g/day. May need to go lower for certain patients.
- Low protein diet with supplemental NAC + taurine or NAC+P5P, both resulted in increase in eGFR, but NAC+P5P strongest with an increase of eGFR ~8.5. Both treatments worked better in patients at stages 3b and above with no signs of acidosis.

Li, S., & Susztak, K. (2025). Nature Reviews Nephrology, 21(2), 77–78. <https://doi.org/10.1038/s41581-024-00919-w>
Rapa, S. F., Di Iorio, B. R., Campiglia, P., Heidland, A., & Marzocco, S. (2020). International Journal of Molecular Sciences (Vol. 21, Issue 1). <https://doi.org/10.3390/ijms21010263>
Cecchini, V., Troise, D., Sabatino, A., Cicirelli, A., et al. (2025). Journal of Renal Nutrition, 0(0). <https://doi.org/10.1053/j.jrn.2025.08.002>
Chen, J., Wu, J., Kong, D., Yang, C., Yu, H., Pan, Q., Liu, W., Ding, Y., & Liu, H. (2020). Journal of Renal Nutrition, 30(2), 101–110. <https://doi.org/https://doi.org/10.1053/j.jrn.2019.06.011>
Oliveira, M. W. S., Minotto, J. B., de Oliveira, M. R., Zanotto-Filho, et al. (2010). Pharmacological Reports : PR, 62(1), 185–193. [https://doi.org/10.1016/s1734-1140\(10\)70256-5](https://doi.org/10.1016/s1734-1140(10)70256-5)
Jannatifar, R., Parivar, K., Roodbari, N. H., & Nasr-Esfahani, M. H. (2020). International Journal of Fertility and Sterility, 14(3), 171–175. <https://doi.org/10.22074/ijfs.2020.44411>

Sharma B, Yadav DK. J Pers Med. 2023;13(2). doi:10.3390/jpm13020298
Bergstrom J, Alverstrand A, Furst P, Lindholm B. J Intern Med. 1989;226(3):189-194. doi:https://doi.org/10.1111/j.1365-2796.1989.tb01378.x
Moludi J, Qaisar SA, Kadhim MM, Ahmadi Y, Davari M. Nutr Metab. 2022;19(1):1-11. doi:10.1186/s12986-022-00684-2
Suliman ME, Bárány P, Filho JCD, Lindholm B, Bergström J. Nephrol Dial Transplant. 2002;17(3):528-529. doi:10.1093/ndt/17.3.528
Dludla P V, Dias SC, Obonye N, Johnson R, Louw J, Nkambule BB. Am J Cardiovasc Drugs. 2018;18(4):283-298. doi:10.1007/s40256-018-0275-2
Sengupta P, Biswas S, Roy T. J Assoc Physicians India. 2022;70(5):11-12. <http://europepmc.org/abstract/MED/35598122>

Summary of Integrative Interventions



DIET



EXERCISE



REDUCE STRESS



IMPROVE SLEEP

- Reduce toxin exposure/load.
- Only small number of trials on the use of pre/probiotics in renal patients.
- Constipation is a major issue for CKD that leads to increased uraemic toxins. Increase waste excretion through other pathways; fibre and polyphenols are vital. Also treats the chronic inflammation and aids gut permeability.
- Curcumin, quercetin, rutin, resveratrol, hibiscus, anthocyanins.
- Bonus effects helpful for hypertension and metabolic syndrome.

Saglimbene, V. M., Wong, G., van Zwieten, A., Palmer, S. C., Ruospo, M., Natale, P., Campbell, K., Teixeira-Pinto, A., Craig, J. C., & Strippoli, G. F. M. (2020). Clinical Nutrition, 39(2), 358–368.
Rapa, S. F., Di Iorio, B. R., Campiglia, P., Heidland, A., & Marzocco, S. (2020). International Journal of Molecular Sciences (Vol. 21, Issue 1). <https://doi.org/10.3390/ijms21010263>

Chen, J., Wu, J., Kong, D., Yang, C., Yu, H., Pan, Q., Liu, W., Ding, Y., & Liu, H. (2020). Journal of Renal Nutrition, 30(2), 101–110. <https://doi.org/https://doi.org/10.1053/j.jrn.2019.06.011>
Oliveira, M. W. S., Minotto, J. B., de Oliveira, M. R., Zanotto-Filho, A., Behr, G. A., Rocha, R. F., Moreira, J. C. F., & Klamt, F. (2010). Pharmacological Reports: PR, 62(1), 185–193. [https://doi.org/10.1016/s1734-1140\(10\)70256-5](https://doi.org/10.1016/s1734-1140(10)70256-5)

McFarlane C, Ramos CI, Johnson DW, Campbell KL. J Ren Nutr. 2019;29(3):209-220. doi:10.1053/j.jrn.2018.08.008
Ramos CI, Armani RG, Canziani ME, et al. J Ren Nutr. 2020;30(1):31-35. doi:10.1053/j.jrn.2019.02.004
Dai W, Lu H, Chen Y, Yang D, Sun L, He L. Front Cell Dev Biol. 2021;9(August):1-11. doi:10.3389/fcell.2021.706832

Summary of Integrative Interventions & Considerations



- Treating malnutrition is key:
 - Minerals: **Zinc** 20mg, Iron, **Magnesium** 300-600 mg (depends on vit D levels >50ng/ml/ 125 nmol/L), **Selenium** and Copper. Citrate form is very useful. Can also look at bicarbonates as well.
 - Detox and methylation: **methyl B12**, **SAMe**, **folates**, **histidine**, **taurine**, **NAC**, **carnosine**, **sulforaphane**.
 - Fats (brain +CVD): Omega 3 - 4g total (**1.6 g of EPA and 0.8 g of DHA**), **phospholipids**, **choline**.
 - Muscle health: **HMB 3g**, **creatine 3-5g**.
 - Mitochondrial metabolic: **CoQ 10** (300-600 mg, any form), **B3/NAD booster**, **lipoic acid**, **acetyl-l-carnitine**, **resveratrol**, **inositol**
 - Cardiovascular: **citrulline**, **hibiscus anthocyanins**, **vitamin K2**, **taurine**, **P5P**, **B12** (homocysteine issue)
 - Vitamins: full spectrum (**A,B,C,D,E,K**). Although E less important, **Vitamin D is mandatory**.

Nephrotoxic Drugs

- Drugs altering intraglomerular haemodynamic:
 - ACEi, ARBs, NSAIDs, Cyclosporine, Tacrolimus
- Drugs associated with tubular cell toxicity:
 - Aminoglycosides, Amphotericin B, Contrast dye.
- Drugs associated with chronic interstitial nephropathy:
 - Acetaminophen, Aspirin, NSAIDs, Lithium (long term, high dosage)
- Drugs associated with crystal nephropathy:
 - Acyclovir, Methotrexate, Sulfa antibiotics (Sulfonamides) and Triamterene.
- Other drugs:
 - Proton pump inhibitors, Benzodiazepines, Fluoxetine, Statins, Diazepam and other sleeping pills

Hall, R. K., Kazancioğlu, R., Thanachayanont, T., Wong, G., Sabanayagam, D., et al. (2024). Nature Reviews Nephrology, 20(6), 386–401. <https://doi.org/10.1038/s41581-024-00823-3>

Liao CY, Chung CH, Lu KC, et al. Front Pharmacol. 2021;11(January):1-9. doi:10.3389/fphar.2020.524113

Bae E, Lee TW, Park DJ. J Korean Med Assoc. 2020;63(1):30-35. doi:10.5124/JKMA.2020.63.1.30

Varga Z, Sabzwari S rafay ali, Vargova V. Cureus. 2017;9(4). doi:10.7759/cureus.1144

Agarwal, R., Verma, A., & Georgianos, P. I. (2025). Nature Reviews Nephrology, 21(4), 264–278. <https://doi.org/10.1038/s41581-024-00918-x>

Herbal Options

What NOT to take

x **Toxins & irritants:**

Aristolochic acid (in many TCM herbs), *Artemisia absinthium*, asparagus root, *autumn crocus*, buchu leaves, cat's claw, ciandanol, Black pearl, horse chestnut, juniper berries, lovage root, parsley, periwinkle, sassafras, Tung shueh, *Vandelia cordifolia*

x **Use with caution - they may be useful to improve markers but may further damage the kidney or diuretic action that can change mineral balance:**

Alfalfa, buckthorn (*rhamnus* species), ginger, nettle, vervain, aloe, ginseng, noni juice, bayberry, cascara, horsetail, panax, blue cohosh, coltsfoot, Liquorice, rhubarb, broom, dandelion, mate, senna

What could be useful

- ✓ Astragalus
- ✓ Allicin (garlic)
- ✓ Beetroot (nitrates for NO)
- ✓ Silymarin
- ✓ Herbs that offer anti-inflammatory, anti-oxidative effects and enhance blood flow. Can be a double edged sword.
- ✓ Curcumin, quercetin, rutin, resveratrol, hibiscus anthocyanins.
- ✓ Dark chocolate - AE with the caffeine causing increased heart rate initially with non-regular consumers.

Ultimate Dietary Recommendations

- Alkaline diet and high in citrates offer protection from unwanted metabolites from protein metabolism.
- Don't forget gut health!
- Protein content is based on stages of CKD:
 - 0.8–1.0 g/kg ideal body weight (IBW)/day for patients with stage 4–5 CKD not on dialysis
 - 1.1–1.4 g/kg IBW/day for patients treated on maintenance haemodialysis
 - 1.0–1.2 g/kg IBW/day for patients treated with peritoneal dialysis
- Reduce protein to allow for supplemental key and essential amino acids.
 - Improve albumin levels on haemodialysis (not peritoneal) by giving 3.6g essential amino acid supplement. Improvements were also seen in grip strength and SF-12 mental health score.
 - Retrospective cohort study has shown low protein diet + key aminos + keto-analogs vs low protein diet resulted in increased time to renal transplant 345 vs 220 days ($p=0.001$).

General Treatment Strategy Through Stages of CKD

- Gut health is a good indicator of renal function. Looking after one of two remaining waste removal pathways is vital. Sweating is another alternate way to remove urea and other toxins.
- Mitochondrial nutrients are key focus throughout CKD.
- **Stage 1-2:**
 - Work out what's driving kidney function loss, treat the co-morbid conditions, explore alternative medications to renal toxic drugs. Mediterranean diet, like anti-inflammatory/alkaline or DASH diet, looking for high intake of plant foods. Look out for rate of decline of eGFR.
- **Stage 3:**
 - More targeted renal protective intervention, must monitor supplementation for side effects; adjust accordingly. Start to implement "lower" protein diet with supplemental amino acids. Start to reduce potassium and phosphates. Digestive enzymes and betaine hydrochloride are important as reduced production is seen in CKD.
- **Stage 4 & 5:**
 - Will require reduction in supplementation as metabolites can be toxic, use low dosages. Moving from gram amino acid supplementation to mg supplementation. Need to rely on other methods of excretion: sweat and making sure gut function is optimal. Detox pathways heavily hit and need more "antioxidant defence". Controlling uraemic toxin production and effects
- **ESKD on dialysis:**
 - Supplement after dialysis sessions, return to higher dosages every 2 to 3 days as nutrients will be stripped.
 - Malnutrition is major issue.
 - Sarcopenia is a big risk, along with immunity.

Take Home Messages

- It's a hidden disease
- Watch eGFR rate of decline
- Disease of Malnutrition: Control protein to support supplemental amino acids
- Diet that is anti-inflammatory and low acid load. More plants in the diet; watch for potassium.
- Mitochondrial nutrients to support repair and function.

Exclusive event offer



THE NEURO RESILIENCE SUMMIT

RECOVERING THE SLEEP-BRAIN-BODY CONNECTION



Scan QR or visit
bioconcepts.com.au/events
to learn more!

VIRTUAL TICKET AUD \$284 ~~\$395~~ save \$111

IN-PERSON TICKET AUD \$540 ~~\$749~~ save \$209

Code: NREM20 for an EXTRA 20% off Limited Early Bird Tickets

References

- Agarwal, R., Verma, A., & Georgianos, P. I. (2025). Diuretics in patients with chronic kidney disease. *Nature Reviews Nephrology*, 21(4), 264–278. <https://doi.org/10.1038/s41581-024-00918-x>
- Akbar, A., Drakowski, R., VanOrmer, M., Rapoza, R., Hahka, T., Freil, C., Natarajan, S. K., Thoene, M., Hanson, C., Anderson-Berry, A., & Mauch, T. (2025). Relationship Between Maternal Plasma Retinol and Provitamin A Carotenoids With Fetal and Infant Kidney Development: A Comprehensive Analysis. *Journal of Renal Nutrition*, 35(6), 708–717. <https://doi.org/10.1053/j.jrn.2025.07.006>
- Alelign, T., & Petros, B. (2018). Kidney Stone Disease: An Update on Current Concepts. *Advances in Urology*, 2018. <https://doi.org/10.1155/2018/3068365>
- Allerton, T. D., Proctor, D. N., Stephens, J. M., Dugas, T. R., Spielmann, G., & Irving, B. A. (2018). L-citrulline supplementation: Impact on cardiometabolic health. *Nutrients*, 10(7), 1–24. <https://doi.org/10.3390/nu10070921>
- Asgharpour, M., Khavandegar, A., Balaei, P., Enayati, N., Mardi, P., Alirezaei, A., & Bakhtiyari, M. (2021). Efficacy of Oral Administration of Allium sativum Powder “garlic Extract” on Lipid Profile, Inflammation, and Cardiovascular Indices among Hemodialysis Patients. *Evidence-Based Complementary and Alternative Medicine*, 2021. <https://doi.org/10.1155/2021/6667453>
- Athinarayanan, S. J., Roberts, C. G. P., Vangala, C., Shetty, G. K., McKenzie, A. L., Weimbs, T., & Volek, J. S. (2024). The case for a ketogenic diet in the management of kidney disease. *BMJ Open Diabetes Research & Care*, 12(2). <https://doi.org/10.1136/bmjdr-2024-004101>
- Australian Institute of Health and Welfare. (2023). Chronic Kidney Disease: Australian Facts. *Australian Government*, (February), 1–121.
- Babitt, J. L., & Lin, H. Y. (2012). Mechanisms of anemia in CKD. *Journal of the American Society of Nephrology*, 23(10), 1631–1634. <https://doi.org/10.1681/ASN.2011111078>
- Bae, E., Lee, T. W., & Park, D. J. (2020). Drug-induced nephrotoxicity. *Journal of the Korean Medical Association*, 63(1), 30–35. <https://doi.org/10.5124/JKMA.2020.63.1.30>
- Ballew, S. H., Zhou, L., Surapaneni, A., Grams, M. E., Windham, B. G., Selvin, E., Coresh, J., Miao, S., Inker, L. A., & Levey, A. S. (2023). A Novel Creatinine Muscle Index Based on Creatinine Filtration: Associations with Frailty and Mortality. *Journal of the American Society of Nephrology*. https://journals.lww.com/jasn/Fulltext/9900/A_Novel_Creatinine_Muscle_Index_Based_on.65.aspx
- Banerjee, T., McCulloch, C. E., Crews, D. C., Burrows, N. R., Paykov, M. E., Saran, R., Morgenstern, H., Bragg-Gresham, J., & Powe, N. R. (2022). Pro-inflammatory diets and risk of end-stage kidney disease in U.S. adults with chronic kidney disease. *Kidney360*, 3, 10.34067/KID.0000442022. <https://doi.org/10.34067/kid.0000442022>

References

- Bargagli, M., Scoglio, M., Howles, S. A., & Fuster, D. G. (2025). Kidney stone disease: Risk factors, pathophysiology and management. *Nature Reviews Nephrology*, 21(11), 794–808. <https://doi.org/10.1038/s41581-025-00990-x>
- Baylis, C. (2008). Nitric oxide deficiency in chronic kidney disease. *American Journal of Physiology - Renal Physiology*, 294(1). <https://doi.org/10.1152/ajprenal.00424.2007>
- Bergström, J. (1995). Nutrition and mortality in hemodialysis. *Journal of the American Society of Nephrology*, 6(5). https://journals.lww.com/jasn/Fulltext/1995/11000/Nutrition_and_mortality_in_hemodialysis_2.aspx
- BERGSTRÖM, J., ALVESTRAND, A., FÜRST, P., & LINDHOLM, B. (1989). Sulphur amino acids in plasma and muscle in patients with chronic renal failure: Evidence for taurine depletion. *Journal of Internal Medicine*, 226(3), 189–194. <https://doi.org/10.1111/j.1365-2796.1989.tb01378.x>
- Black, A. P., Anjos, J. S., Cardozo, L., Carmo, F. L., Dolenga, C. J., Nakao, L. S., de Carvalho Ferreira, D., Rosado, A., Carraro Eduardo, J. C., & Mafra, D. (2018). Does Low-Protein Diet Influence the Uremic Toxin Serum Levels From the Gut Microbiota in Nondialysis Chronic Kidney Disease Patients? *Journal of Renal Nutrition*, 28(3), 208–214. <https://doi.org/10.1053/j.jrn.2017.11.007>
- Bloom, P. P., Garrett, W. S., Penniston, K. L., Winkler, M.-K. H., Hazen, S. L., Agudelo, J., Suryavanshi, M., Babiker, A., Dodd, D., Fischbach, M. A., Huang, K. C., Huttenhower, C., Joe, B., Kalantar-Zadeh, K., Knight, R., Miller, A. W., Rabb, H., Srivastava, A., Tang, W. H. W., ... Pluznick, J. L. (2025). Microbiota and kidney disease: The road ahead. *Nature Reviews Nephrology*, 21(10), 702–716. <https://doi.org/10.1038/s41581-025-00988-5>
- Bowe, B., Xie, Y., Xu, E., & Al-Aly, Z. (2021). Kidney outcomes in long COVID. *Journal of the American Society of Nephrology*, 32(11), 2851–2862. <https://doi.org/10.1681/ASN.2021060734>
- Brosnan, M. E., & Brosnan, J. T. (2004). Renal Arginine Metabolism. *The Journal of Nutrition*, 134(10), 2791S-2795S. <https://doi.org/10.1093/jn/134.10.2791S>
- Brosnan, M. E., & Brosnan, J. T. (2020). Histidine metabolism and function. *Journal of Nutrition*, 150, 2570S-2575S. <https://doi.org/10.1093/jn/nxaa079>
- Buchanan, S., Combet, E., Stenvinkel, P., & Shiels, P. G. (2020). Klotho, Aging, and the Failing Kidney. *Frontiers in Endocrinology*, 11(August), 1–15. <https://doi.org/10.3389/fendo.2020.00560>
- Buchholz, P. (2014). Renal Vitamins Revisited. *Journal of Renal Nutrition*, 24(4), e27–e29. <https://doi.org/10.1053/j.jrn.2014.04.004>

References

- Bullock, G. C., Richardson, C. L., Schrott, V., Gunawardena, N. D., Cole, T. N., Corey, C. G., & Shiva, S. S. (2015). The Role of Mitochondrial Metabolism and Redox Signaling in Iron Deficiency Anemia. *Blood*, 126(23), 2145. <https://doi.org/10.1182/blood.V126.23.2145.2145>
- Burch, J. S., Marcero, J. R., Maschek, J. A., Cox, J. E., Jackson, L. K., Medlock, A. E., Phillips, J. D., & Dailey, H. A. (2018). Glutamine via α -ketoglutarate dehydrogenase provides succinyl-CoA for heme synthesis during erythropoiesis. *Blood*, 132(10), 987–998. <https://doi.org/10.1182/blood-2018-01-829036>
- Calvo, M. S., & Uribarri, J. (2025). Underappreciated Health Benefits of Edible Mushrooms in the Dietary Management of Chronic Kidney Disease. *Journal of Renal Nutrition*, 0(0). <https://doi.org/10.1053/j.jrn.2025.09.002>
- Capasso, G., Franssen, C. F. M., Perna, A. F., Massy, Z. A., Menzies, R. I., Zoccali, C., Tessitore, A., Nedergaard, M., Okusa, M. D., Ortiz, A., Wagner, C. A., & Unwin, R. J. (2025). Drivers and mechanisms of cognitive decline in chronic kidney disease. *Nature Reviews Nephrology*, 21(8), 536–552. <https://doi.org/10.1038/s41581-025-00963-0>
- Carville, S., Wonderling, D., & Stevens, P. (2014). Early identification and management of chronic kidney disease in adults: Summary of updated NICE guidance. *BMJ*, 349, g4507. <https://doi.org/10.1136/bmj.g4507>
- Cecchini, V., Troise, D., Sabatino, A., Cicirelli, A., Hallergård, G., Avesani, C. M., & Stenvinkel, P. (2025a). Optimizing Mitochondrial Targeting With Bioactive Compounds: Dietary Pattern Considerations for Patients With Chronic Kidney Disease. *Journal of Renal Nutrition*, 0(0). <https://doi.org/10.1053/j.jrn.2025.08.002>
- Cecchini, V., Troise, D., Sabatino, A., Cicirelli, A., Hallergård, G., Avesani, C. M., & Stenvinkel, P. (2025b). Optimizing Mitochondrial Targeting With Bioactive Compounds: Dietary Pattern Considerations for Patients With Chronic Kidney Disease. *Journal of Renal Nutrition*, 0(0). <https://doi.org/10.1053/j.jrn.2025.08.002>
- Cerda, J., Kashani, K., Ostermann, M., Basu, R. K., Bell, S., Cantaluppi, V., Chakaravarthi, R., Costa, J. M., Claire-Del Granado, R., Macedo, E., Rhee, H., Srisawat, N., Wu, V.-C., Yang, L., & Mehta, R. L. (2026). The global epidemiology of acute kidney injury: Challenges and opportunities. *Nature Reviews Nephrology*, 22(3), 179–198. <https://doi.org/10.1038/s41581-025-01030-4>
- Chandra, S., Ravula, S., Errabelli, P., Spencer, H., & Singh, M. (2023). No Good Deed: Acidosis in Chronic Kidney and Liver Disease. *Journal of Renal Nutrition*, 33(3), 499–502. <https://doi.org/10.1053/j.jrn.2022.12.008>
- Chen, J., Wu, J., Kong, D., Yang, C., Yu, H., Pan, Q., Liu, W., Ding, Y., & Liu, H. (2020). The Effect of Antioxidant Vitamins on Patients With Diabetes and Albuminuria: A Meta-Analysis of Randomized Controlled Trials. *Journal of Renal Nutrition*, 30(2), 101–110. <https://doi.org/10.1053/j.jrn.2019.06.011>
- Chen, K.-T., Kang, Y.-N., Lin, Y.-C., Tsai, I.-L., Chang, W.-C., Fang, T.-C., Wu, M.-S., & Kao, C.-C. (2021). Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Kidney Failure Patients Treated with Dialysis: A Systematic Review and Meta-Analysis. *Clinical Journal of the American Society of Nephrology*, 16(6). https://journals.lww.com/cjasn/Fulltext/2021/06000/Efficacy_and_Safety_of_Mineralocorticoid_Receptor.14.aspx
- Chen, W., & Abramowitz, M. K. (2014). Metabolic acidosis and the progression of chronic kidney disease. *BMC Nephrology*, 15(1), 1–8. <https://doi.org/10.1186/1471-2369-15-55>

References

- Cheu, C., Pearson, J., Dahlerus, C., Lantz, B., Chowdhury, T., Sauer, P. F., Farrell, R. E., Port, F. K., & Ramirez, S. P. B. (2013). Association between oral nutritional supplementation and clinical outcomes among patients with ESRD. *Clinical Journal of the American Society of Nephrology*, 8(1), 100–107. <https://doi.org/10.2215/CJN.13091211>
- Cho, E. S., Anderson, H. L., Wixom, R. L., Hanson, K. C., & Krause, G. F. (1984). Long-Term Effects of Low Histidine Intake on Men. *The Journal of Nutrition*, 114(2), 369–384. <https://doi.org/10.1093/jn/114.2.369>
- Clarke, H., Kim, D. H., Meza, C. A., Ormsbee, M. J., & Hickner, R. C. (2020). The evolving applications of creatine supplementation: Could creatine improve vascular health? *Nutrients*, 12(9), 1–23. <https://doi.org/10.3390/nu12092834>
- Clementi, A., Virzi, G. M., Goh, C. Y., Cruz, D. N., Granata, A., Vescovo, G., & Ronco, C. (2013). Cardiorenal Syndrome Type 4: A Review. *Cardiorenal Medicine*, 3(1), 63–70. <https://doi.org/10.1159/000350397>
- Combe, C., Alencar de Pinho, N., Guedes, M., Frimat, L., Fouque, D., Liabeuf, S., Niang, A., Kanjanabuch, T., Stengel, B., Massy, Z. A., & Pecoits-Filho, R. (2026). Optimal patient care in advanced chronic kidney disease progressing to kidney failure. *Nature Reviews Nephrology*, 1–16. <https://doi.org/10.1038/s41581-026-01056-2>
- Copur, S., Berkkan, M., Basile, C., Tuttle, K., & Kanbay, M. (2022). Post-acute COVID-19 syndrome and kidney diseases: What do we know? *Journal of Nephrology*, 35(3), 795–805. <https://doi.org/10.1007/s40620-022-01296-y>
- Crosby, L., Davis, B., Joshi, S., Jardine, M., Paul, J., Neola, M., & Barnard, N. D. (2021). Ketogenic Diets and Chronic Disease: Weighing the Benefits Against the Risks. *Frontiers in Nutrition*, 8(July), 1–11. <https://doi.org/10.3389/fnut.2021.702802>
- Cruz-Mora, J., Martínez-Hernández, N. E., Martín del Campo-López, F., Viramontes-Hörner, D., Vizmanos-Lamotte, B., Muñoz-Valle, J. F., García-García, G., Parra-Rojas, I., & Castro-Alarcón, N. (2014). Effects of a Symbiotic on Gut Microbiota in Mexican Patients With End-Stage Renal Disease. *Journal of Renal Nutrition*, 24(5), 330–335. <https://doi.org/10.1053/j.jrn.2014.05.006>
- Dai, W., Lu, H., Chen, Y., Yang, D., Sun, L., & He, L. (2021). The Loss of Mitochondrial Quality Control in Diabetic Kidney Disease. *Frontiers in Cell and Developmental Biology*, 9(August), 1–11. <https://doi.org/10.3389/fcell.2021.706832>
- D'Alessandro, C., Giannese, D., Piccoli, G. B., Panichi, V., & Cupisti, A. (2025). Ketogenic diets in chronic kidney disease patients: A review for skeptics by skeptics. *Journal of Nephrology*, 38(6), 1541–1556. <https://doi.org/10.1007/s40620-025-02285-7>
- de Guingand, D. L., Palmer, K. R., Snow, R. J., Davies-Tuck, M. L., & Ellery, S. J. (2020). Risk of adverse outcomes in females taking oral creatine monohydrate: A systematic review and meta-analysis. *Nutrients*, 12(6), 1–26. <https://doi.org/10.3390/nu12061780>
- de Souza e Silva, A., Pertille, A., Reis Barbosa, C. G., Aparecida de Oliveira Silva, J., de Jesus, D. V., Ribeiro, A. G. S. V., Baganha, R. J., & de Oliveira, J. J. (2019). Effects of Creatine Supplementation on Renal Function: A Systematic Review and Meta-Analysis. *Journal of Renal Nutrition*, 29(6), 480–489. <https://doi.org/10.1053/j.jrn.2019.05.004>
- Derakhshandeh-Rishehri, S.-M., Franco, L. P., Kalhoff, H., Wudy, S. A., & Remer, T. (2025). Higher Renal Net Acid, but Not Higher Phosphate Excretion During Growth Associates With Lower Adult Circulating Uromodulin. *Journal of Renal Nutrition*, 35(6), 726–733. <https://doi.org/10.1053/j.jrn.2024.12.002>
- Deschemin, J. C., & Vaulont, S. (2013). Role of Hepcidin in the Setting of Hypoferremia during Acute Inflammation. *PLoS ONE*, 8(4), 1–7. <https://doi.org/10.1371/journal.pone.0061050>
- Devuyst, O., Olinger, E., & Rampoldi, L. (2017). Uromodulin: From physiology to rare and complex kidney disorders. *Nature Reviews Nephrology*, 13(9), 525–544. <https://doi.org/10.1038/nrneph.2017.101>
- Dharnidharka, V. R., Kwon, C., & Stevens, G. (2002). Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis. *American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation*, 40(2), 221–226. <https://doi.org/10.1053/ajkd.2002.34487>
- Dhawan, S., & Olweny, E. O. (2020). Phyllanthus niruri (stone breaker) herbal therapy for kidney stones; a systematic review and meta-analysis of clinical efficacy, and Google Trends analysis of public interest. *The Canadian Journal of Urology*, 2(27), 10162–10166.

References

- Dines, V. A., & Garovic, V. D. (2023). Menopause and chronic kidney disease. *Nature Reviews Nephrology*. <https://doi.org/10.1038/s41581-023-00717-w>
- Dinicolantonio, J. J., McCarty, M. F., & Okeefe, J. H. (2018). Role of dietary histidine in the prevention of obesity and metabolic syndrome. *Open Heart*, 5(2), 1–4. <https://doi.org/10.1136/openhrt-2017-000676>
- Dlodla, P. V., Dias, S. C., Obonye, N., Johnson, R., Louw, J., & Nkambule, B. B. (2018). A Systematic Review on the Protective Effect of N-Acetyl Cysteine Against Diabetes-Associated Cardiovascular Complications. *American Journal of Cardiovascular Drugs*, 18(4), 283–298. <https://doi.org/10.1007/s40256-018-0275-2>
- Drechsler, C., Kollerits, B., Meinitzer, A., März, W., Ritz, E., König, P., Neyer, U., Pilz, S., Wanner, C., & Kronenberg, F. (2013). Homoarginine and Progression of Chronic Kidney Disease: Results from the Mild to Moderate Kidney Disease Study. *PLoS ONE*, 8(5), 4–9. <https://doi.org/10.1371/journal.pone.0063560>
- Duranton, F., Lundin, U., Gayraud, N., Mischak, H., Aparicio, M., Mourad, G., Daurès, J. P., Weinberger, K. M., & Argilés, À. (2014). Plasma and urinary amino acid metabolomic profiling in patients with different levels of kidney function. *Clinical Journal of the American Society of Nephrology*, 9(1), 37–45. <https://doi.org/10.2215/CJN.06000613>
- Dwyer, J. P., & Kelepouris, E. (2023). New Directions in Phosphorus Management in Dialysis. *Journal of Renal Nutrition*, 33(1), 12–16. <https://doi.org/10.1053/j.jrn.2022.04.006>
- El-arif, G., Farhat, A., Khazaal, S., Annweiler, C., Kovacic, H., Wu, Y., Cao, Z., Fajloun, Z., Khattar, Z. A., & Sabatier, J. M. (2021). The Renin-Angiotensin System: A Key Role in. *Molecules*, 26(22), 1–31.
- Eustace, J. A., Coresh, J., Kutchev, C., Te, P. L., Gimenez, L. F., Scheel, P. J., & Walser, M. (2000). Randomized double-blind trial of oral essential amino acids for dialysis-associated hypoalbuminemia. *Kidney International*, 57(6), 2527–2538. <https://doi.org/10.1046/j.1523-1755.2000.00112.x>
- Falconi, C. A., Junho, C. V. da C., Fogaça-Ruiz, F., Vernier, I. C. S., da Cunha, R. S., Stinghen, A. E. M., & Carneiro-Ramos, M. S. (2021). Uremic Toxins: An Alarming Danger Concerning the Cardiovascular System. *Frontiers in Physiology*, 12(May), 1–20. <https://doi.org/10.3389/fphys.2021.686249>
- Ferguson, T. W., Whitlock, R. H., Bamforth, R. J., Beaudry, A., Darcel, J., Di Nella, M., Rigatto, C., Tangri, N., & Komenda, P. (2021). Cost-Utility of Dialysis in Canada: Hemodialysis, Peritoneal Dialysis, and Nondialysis Treatment of Kidney Failure. *Kidney Medicine*, 3(1), 20–30.e1. <https://doi.org/10.1016/j.xkme.2020.07.011>
- Gargiulo, L., Hendriks-Balk, M., Theiler, K., Brito, W., Corre, T., Wuerzner, G., & Pruijm, M. (2025). The Acute Effect of Dark Chocolate on Blood Pressure and Renal Hemodynamics as Assessed With Doppler Ultrasound in Healthy Volunteers. *Journal of Renal Nutrition*, 35(4), 486–493. <https://doi.org/10.1053/j.jrn.2025.02.003>
- Garibotto Giacomo, G., Sofia, A., Saffioti, S., Bonanni, A., Mannucci, I., & Verzola, D. (2010). Amino acid and protein metabolism in the human kidney and in patients with chronic kidney disease. *Clinical Nutrition*, 29(4), 424–433. <https://doi.org/10.1016/j.clnu.2010.02.005>

References

- Gigliotti, J. C., & Okusa, M. D. (2014). The spleen: The forgotten organ in acute kidney injury of critical illness. *Nephron - Clinical Practice*, 127(1–4), 153–157. <https://doi.org/10.1159/000363255>
- Glorieux, G., Burtsey, S., Evenepoel, P., Jankowski, J., Koppe, L., Masereeuw, R., & Vanholder, R. (2026). A guide to uraemic toxicity. *Nature Reviews Nephrology*, 22(1), 50–68. <https://doi.org/10.1038/s41581-025-01006-4>
- Gomes-Neto, A. W., Osté, M. C. J., Sotomayor, C. G., van den Berg, E., Geleijnse, J. M., Berger, S. P., Gans, R. O. B., Bakker, S. J. L., & Navis, G. J. (2020). Mediterranean style diet and kidney function loss in kidney transplant recipients. *Clinical Journal of the American Society of Nephrology*, 15(2), 238–246. <https://doi.org/10.2215/CJN.06710619>
- Goraya, N., & Wesson, D. E. (2017). Is dietary red meat kidney toxic? *Journal of the American Society of Nephrology*, 28(1), 5–7. <https://doi.org/10.1681/ASN.2016060664>
- Gualano, B., de Salles Painelli, V., Roschel, H., Lugaresi, R., Dorea, E., Artioli, G. G., Lima, F. R., da Silva, M. E. R., Cunha, M. R., Seguro, A. C., Shimizu, M. H., Otaduy, M. C. G., Sapienza, M. T., da Costa Leite, C., Bonfá, E., & Lancha Junior, A. H. (2011). Creatine supplementation does not impair kidney function in type 2 diabetic patients: A randomized, double-blind, placebo-controlled, clinical trial. *European Journal of Applied Physiology*, 111(5), 749–756. <https://doi.org/10.1007/s00421-010-1676-3>
- Gur, E., Levy, D., Topaz, G., Naser, R., Wand, O., Kitay-Cohen, Y., Benchetrit, S., Sarel, E., & Cohen-Hagai, K. (2022). Disease severity and renal outcomes of patients with chronic kidney disease infected with COVID-19. *Clinical and Experimental Nephrology*, 26(5), 445–452. <https://doi.org/10.1007/s10157-022-02180-6>
- Hahn, D., Hodson, E. M., & Fouque, D. (2020). Low protein diets for non-diabetic adults with chronic kidney disease. *Cochrane Database of Systematic Reviews*, 2020(11). <https://doi.org/10.1002/14651858.CD001892.pub5>
- Hall, R. K., Kazancıoğlu, R., Thanachayanont, T., Wong, G., Sabanayagam, D., Battistella, M., Ahmed, S. B., Inker, L. A., Barreto, E. F., Fu, E. L., Clase, C. M., & Carrero, J. J. (2024). Drug stewardship in chronic kidney disease to achieve effective and safe medication use. *Nature Reviews Nephrology*, 20(6), 386–401. <https://doi.org/10.1038/s41581-024-00823-3>
- Hamilton, A. D. K., Sparsoe, L. V., Skov, M., Johnsen, N., Christensen, M. H., Corydon, T. J., & Praetorius, H. (2024). Increased water intake dilutes protective uromodulin levels in urine and results in increased rates of pyelonephritis in a murine model. *Acta Physiologica*, 240(9), e14204. <https://doi.org/10.1111/apha.14204>
- Hamza, E., Metzinger, L., & Metzinger-Le Meuth, V. (2020). Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review. *Cells*, 9(9). <https://doi.org/10.3390/cells9092039>
- Han, M., Moon, S., Lee, S., Kim, K., An, W. J., Ryu, H., Kang, E., Ahn, J.-H., Sung, H. Y., Park, Y. S., Lee, S. E., Lee, S.-H., Jeong, K. H., Ahn, C., Kelly, T. N., Hsu, J. Y., Feldman, H. I., Park, S. K., & Oh, K.-H. (2023). Novel Genetic Variants Associated with Chronic Kidney Disease Progression. *Journal of the American Society of Nephrology*. https://journals.lww.com/jasn/Fulltext/9900/Novel_Genetic_Variants_Associated_with_Chronic.39.aspx
- Handelman, G. J. (2011). New Insight on Vitamin C in Patients With Chronic Kidney Disease. *Journal of Renal Nutrition*, 21(1), 110–112. <https://doi.org/10.1053/j.jrn.2010.11.003>
- Hasegawa, S., & Inagi, R. (2023). Molecular mechanisms of kidney crosstalk with distant organs. *Nature Reviews Nephrology*, 19(2), 75–76. <https://doi.org/10.1038/s41581-022-00655-z>

References

- He, F., Antonucci, L., Yamachika, S., Zhang, Z., Taniguchi, K., Umemura, A., Hatzivassiliou, G., Roose-Girma, M., Reina-Campos, M., Duran, A., Diaz-Meco, M. T., Moscat, J., Sun, B., & Karin, M. (2020). NRF2 activates growth factor genes and downstream AKT signaling to induce mouse and human hepatomegaly. *Journal of Hepatology*, 72(6), 1182–1195. <https://doi.org/10.1016/j.jhep.2020.01.023>
- Hering-Smith, K. S., & Hamm, L. L. (2018). Acidosis and citrate: Provocative interactions. *Annals of Translational Medicine*, 6(18), 374–374. <https://doi.org/10.21037/atm.2018.07.37>
- Hill, E., Sapa, H., Negrea, L., Bame, K., Hostetter, T., Barkoukis, H., Dusso, A., & Dobre, M. (2020). Effect of Oat beta-Glucan Supplementation on Chronic Kidney Disease: A Feasibility Study. *Journal of Renal Nutrition*, 30(3), 208–215. <https://doi.org/10.1053/j.jrn.2019.06.012>
- Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O'Callaghan, C. A., Lasserson, D. S., & Hobbs, F. D. R. (2016). Global Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. *PLOS ONE*, 11(7), e0158765.
- Hoorn, E. J., Subramanya, A. R., & Boyd-Shiwerski, C. R. (2026). Potassium and the kidney. *Nature Reviews Nephrology*, 1–16. <https://doi.org/10.1038/s41581-026-01053-5>
- Hsu, C. M., Gupta, S., Tighiouart, H., Goyal, N., Faugno, A. J., Tariq, A., Raichoudhury, R., Sharma, J. H., Meyer, L., Kshirsagar, R. K., Jose, A., Leaf, D. E., Weiner, D. E., Gupta, H., Faugno, G., Raichoudhury, T., Meyer, S., Leaf, K., Walther, C. P., ... Ugwuowo, U. (2022). Kidney Recovery and Death in Critically Ill Patients With COVID-19–Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study. *American Journal of Kidney Diseases*, 79(3), 404–416.e1. <https://doi.org/10.1053/j.ajkd.2021.11.004>
- Huang, H., Li, Y., Liang, J., & Finkelman, F. D. (2018). Molecular regulation of histamine synthesis. *Frontiers in Immunology*, 9(JUN), 1–7. <https://doi.org/10.3389/fimmu.2018.01392>
- Huo, X., Clarke, R., Halsey, J., Jackson, R., Lehman, A., Prince, R., Lewis, J., Baron, J. A., Kroger, H., Sund, R., & Armitage, J. (2023). Calcium Supplements and Risk of CVD: A Meta-Analysis of Randomized Trials. *Current Developments in Nutrition*, 7(3), 100046. <https://doi.org/10.1016/j.cdnut.2023.100046>
- Ikeme, J. C., Scherzer, R., Garimella, P. S., Hallan, S. I., Katz, R., Estrella, M. M., Ix, J. H., & Shlipak, M. G. (2025). Associations of Plasma and Urine Uromodulin With Kidney Disease Progression in Persons With Chronic Kidney Disease and Hypertension: The Systolic Blood Pressure Intervention Trial. *Kidney Medicine*, 7(11), 101118. <https://doi.org/10.1016/j.xkme.2025.101118>
- Ikram, M. A. (2025). Chronic kidney disease and dementia: An epidemiological perspective. *Nature Reviews Nephrology*, 21(8), 525–535. <https://doi.org/10.1038/s41581-025-00967-w>
- Inoue, T., Tanaka, S., & Okusa, M. D. (2017). Neuroimmune Interactions in Inflammation and Acute Kidney Injury. *Frontiers in Immunology*, 8(AUG). <https://doi.org/10.3389/fimmu.2017.00945>
- Investigators, W. C. for the R.-C. (2023). Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support–Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. *JAMA*, 329(14), 1183–1196. <https://doi.org/10.1001/jama.2023.4480>
- Jannatifar, R., Parivar, K., Roodbari, N. H., & Nasr-Esfahani, M. H. (2020). The effect of N-acetyl-cysteine on NRF 2 antioxidant gene expression in asthenoteratozoospermia men: A clinical trial study. *International Journal of Fertility and Sterility*, 14(3), 171–175. <https://doi.org/10.22074/ijfs.2020.44411>
- Jhee, J. H., Kee, Y. K., Park, S., Kim, H., Park, J. T., Han, S. H., Kang, S.-W., & Yoo, T.-H. (2020). High-protein diet with renal hyperfiltration is associated with rapid decline rate of renal function: A community-based prospective cohort study. *Nephrology, Dialysis, Transplantation*, 35(1), 98–106. <https://doi.org/10.1093/ndt/gfz115>

References

- Joshi, S., Shi, R., & Patel, J. (2024). Risks of the ketogenic diet in CKD – the con part. *Clinical Kidney Journal*, 17(1), sfad274. <https://doi.org/10.1093/ckj/sfad274>
- Kalantar-Zadeh, K., & Li, P. K. T. (2020). Strategies to prevent kidney disease and its progression. *Nature Reviews Nephrology*, 16(3), 129–130. <https://doi.org/10.1038/s41581-020-0253-1>
- Kang, M. W., Park, S., Lee, S., Lee, Y., Cho, S., Han, K., Cho, H., Kim, Y., Kim, Y. C., Han, S. S., Lee, H., Lee, J. P., Joo, K. W., Lim, C. S., Kim, Y. S., & Kim, D. K. (2020). Glomerular hyperfiltration is associated with dementia: A nationwide population-based study. *PLOS ONE*, 15(1), e0228361. <https://doi.org/10.1371/journal.pone.0228361>
- Khan, S. R., Pearle, M. S., Robertson, W. G., Gambaro, G., Canales, B. K., Doizi, S., Traxer, O., & Tiselius, H. G. (2016). Kidney stones. *Nature Reviews Disease Primers*, 2, 1–23. <https://doi.org/10.1038/nrdp.2016.8>
- Kimura, K., Nakamura, Y., Inaba, Y., Matsumoto, M., Kido, Y., Asahara, S. I., Matsuda, T., Watanabe, H., Maeda, A., Inagaki, F., Mukai, C., Takeda, K., Akira, S., Ota, T., Nakabayashi, H., Kaneko, S., Kasuga, M., & Inoue, H. (2013). Histidine augments the suppression of hepatic glucose production by central insulin action. *Diabetes*, 62(7), 2266–2277. <https://doi.org/10.2337/db12-1701>
- Knight, J., Madduma-Liyanage, K., Mobley, J. A., Assimos, D. G., & Holmes, R. P. (2016). Ascorbic acid intake and oxalate synthesis. *Urolithiasis*, 44(4), 289–297. <https://doi.org/10.1007/s00240-016-0868-7>
- Knol, M. G. E., Wulfmeyer, V. C., Müller, R.-U., & Rinschen, M. M. (2024). Amino acid metabolism in kidney health and disease. *Nature Reviews Nephrology*, 20(12), 771–788. <https://doi.org/10.1038/s41581-024-00872-8>
- Kuczera, P., Adamczak, M., & Wiecek, A. (2015). Endocrine Abnormalities in Patients with Chronic Kidney Disease. *Prilozi (Makedonska Akademija Na Naukite i Umetnostite. Oddelenie Za Medicinski Nauki)*, 36(2), 109–118. <https://doi.org/10.1515/prilozi-2015-0059>
- Kuro-o, M. (2019). The Klotho proteins in health and disease. *Nature Reviews Nephrology*, 15(1), 27–44. <https://doi.org/10.1038/s41581-018-0078-3>
- Kushiya, A., Nakatsu, Y., Matsunaga, Y., Yamamoto, T., Mori, K., Ueda, K., Inoue, Y., Sakoda, H., Fujishiro, M., Ono, H., & Asano, T. (2016). Role of uric acid metabolism-related inflammation in the pathogenesis of metabolic syndrome components such as atherosclerosis and nonalcoholic steatohepatitis. *Mediators of Inflammation*, 2016. <https://doi.org/10.1155/2016/8603164>
- Kusunoki, H., Tabara, Y., Tsuji, S., Wada, Y., Tamaki, K., Nagai, K., Itoh, M., Sano, K., Amano, M., Maeda, H., Sugita, H., Hasegawa, Y., Kishimoto, H., Shimomura, S., Igase, M., & Shinmura, K. (2022). Estimation of Muscle Mass Using Creatinine/Cystatin C Ratio in Japanese Community-Dwelling Older People. *Journal of the American Medical Directors Association*, 23(5), 902.e21-902.e31. <https://doi.org/10.1016/j.jamda.2021.07.029>
- Lambert, D. C., Kane, J., Slaton, A., & Abramowitz, M. K. (2022). Associations of Metabolic Syndrome and Abdominal Obesity with Anion Gap Metabolic Acidosis among U.S. Adults. *Kidney360*, 3, 10.34067/KID.0002402022. <https://doi.org/10.34067/kid.0002402022>
- Laranjinha, I., Matias, P., & Dickson, J. (2020). Magnesium supplementation to prevent recurrence of renal stones. *Portuguese Journal of Nephrology & Hypertension*, (January). <https://doi.org/10.32932/pjnh.2020.01.048>
- Lau, W. L., & Vaziri, N. D. (2017). The Leaky Gut and Altered Microbiome in Chronic Kidney Disease. *Journal of Renal Nutrition*, 27(6), 458–461. <https://doi.org/10.1053/j.jrn.2017.02.010>

References

- Lee, W.-C., Lee, Y.-T., Li, L., Ng, H., Kuo, W., Lin, P., Liao, Y., Chiou, T., & Lee, C. (2018). The Number of Comorbidities Predicts Renal Outcomes in Patients with Stage 3–5 Chronic Kidney Disease. *Journal of Clinical Medicine*, 7(12), 493. <https://doi.org/10.3390/cm7120493>
- Legrand, M., Bell, S., Forni, L., Joannidis, M., Koyner, J. L., Liu, K., & Cantaluppi, V. (2021). Pathophysiology of COVID-19-associated acute kidney injury. *Nature Reviews Nephrology*, 17(11), 751–764. <https://doi.org/10.1038/s41581-021-00452-0>
- Levey, A. S., Greene, T., Beck, G. J., Caggiula, A. W., Kusek, J. W., Hunsicker, L. G., & Klahr, S. (1999). Dietary protein restriction and the progression of chronic renal disease: What have all of the results of the MDRD study shown? *Journal of the American Society of Nephrology*, 10(11), 2426–2439.
- Lew, Q. L. J., Jafar, T. H., Koh, H. W. L., Jin, A., Chow, K. Y., Yuan, J. M., & Koh, W. P. (2017). Red meat intake and risk of ESRD. *Journal of the American Society of Nephrology*, 28(1), 304–312. <https://doi.org/10.1681/ASN.2016030248>
- Li, S., & Susztak, K. (2025). Mitochondrial dysfunction has a central role in diabetic kidney disease. *Nature Reviews Nephrology*, 21(2), 77–78. <https://doi.org/10.1038/s41581-024-00919-w>
- Liao, C. Y., Chung, C. H., Lu, K. C., Cheng, C. Y., Yang, S. S., Chien, W. C., & Wu, C. C. (2021). Taking Sleeping Pills and the Risk of Chronic Kidney Disease: A Nationwide Population-Based Retrospective Cohort Study. *Frontiers in Pharmacology*, 11(January), 1–9. <https://doi.org/10.3389/fphar.2020.524113>
- Lim, Y. J., Sidor, N. A., Tonial, N. C., Che, A., & Urquhart, B. L. (2021). Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets. *Toxins*, 13(2). <https://doi.org/10.3390/TOXINS13020142>
- Lin, S.-Y., Ju, S.-W., Lin, C. L., Hsu, W.-H., Lin, C.-C., Ting, I.-W., & Kao, C.-H. (2020). Air pollutants and subsequent risk of chronic kidney disease and end-stage renal disease: A population-based cohort study. *Environmental Pollution*, 261, 114154. <https://doi.org/10.1016/j.envpol.2020.114154>
- Lin, T.-Y., & Hung, S.-C. (2026). Protein-Energy Wasting Among Patients With Nondialysis Chronic Kidney Disease: Comparing ISRNM and GLIM Criteria With Malnutrition Inflammation Score. *Journal of Renal Nutrition*, 0(0). <https://doi.org/10.1053/j.jrn.2025.12.006>
- Liu, D., Liu, Z., Ma, J.-Y., Wu, J.-N., Liu, T., & Chen, L.-H. (2025). Associations of Dietary Index Adherence With the Progression of Chronic Kidney Disease Across Cardio-Metabolic Disorders: Findings From Multi-State Models of a Nationwide Cohort Study. *Journal of Renal Nutrition*, 0(0). <https://doi.org/10.1053/j.jrn.2025.10.002>
- Liu, L., Xu, J., Zhang, Z., Ren, D., Wu, Y., Wang, D., Zhang, Y., Zhao, S., Chen, Q., & Wang, T. (2023). Metabolic Homeostasis of Amino Acids and Diabetic Kidney Disease. *Nutrients*, 15(1), 1–19. <https://doi.org/10.3390/nu15010184>
- Liu, M., Zhang, Yanjun, Yang, S., Wu, Q., Ye, Z., Zhou, C., He, P., Zhang, Yuanyuan, Hou, F. F., & Qin, X. (2022). Bidirectional relations between depression symptoms and chronic kidney disease. *Journal of Affective Disorders*, 311, 224–230. <https://doi.org/10.1016/j.jad.2022.05.104>
- Liyanage, T., Toyama, T., Hockham, C., Ninomiya, T., Perkovic, V., Woodward, M., Fukagawa, M., Matsushita, K., Praditpornsilpa, K., Hooi, L. S., Iseki, K., Lin, M. Y., Stirnadel-Farrant, H. A., Jha, V., & Jun, M. (2022). Prevalence of chronic kidney disease in Asia: A systematic review and analysis. *BMJ Global Health*, 7(1), 1–9. <https://doi.org/10.1136/bmjgh-2021-007525>
- Liyanarachi, K. V., Flatby, H., Hallan, S., Åsvold, B. O., Damås, J. K., & Rogne, T. (2025). Uromodulin and Risk of Upper Urinary Tract Infections: A Mendelian Randomization Study. *American Journal of Kidney Diseases*, 85(5), 570-576.e1. <https://doi.org/10.1053/j.ajkd.2024.11.007>

References

- LONG, J. D., STROHBEHN, I. A. N., SAWTELL, R. A. N. I., BHATTACHARYYA, R. O. B. Y., & SISE, M. E. (2022). COVID-19 Survival and its impact on chronic kidney disease. *Translational Research*, 241, 70–82. <https://doi.org/10.1016/j.trsl.2021.11.003>
- Lu, J., Shang, X., Deng, Z., Jiang, S., Wang, S., & Li, W. (2026). Interaction Between Magnesium Intake and Serum 25-Hydroxyvitamin D Levels in Modulating the Likelihood of Chronic Kidney Disease: Evidence from the NHANES 2009-2014. *Journal of Renal Nutrition*, 0(0). <https://doi.org/10.1053/j.jrn.2025.12.008>
- Lyons, O. D. (2024). Sleep disorders in chronic kidney disease. *Nature Reviews Nephrology*, 20(10), 690–700. <https://doi.org/10.1038/s41581-024-00848-8>
- Mafra, D., Kalantar-Zadeh, K., & Moore, L. W. (2021). New Tricks for Old Friends: Treating Gut Microbiota of Patients With CKD. *Journal of Renal Nutrition*, 31(5), 433–437. <https://doi.org/10.1053/j.jrn.2021.07.002>
- Mahalingasivam, V., Su, G., Iwagami, M., Davids, M. R., Wetmore, J. B., & Nitsch, D. (2022). COVID-19 and kidney disease: Insights from epidemiology to inform clinical practice. *Nature Reviews Nephrology*, 18(8), 485–498. <https://doi.org/10.1038/s41581-022-00570-3>
- Mahmoud, T., & Borgi, L. (2021). The Interplay Between Nutrition, Metabolic, and Endocrine Disorders in Chronic Kidney Disease. *Seminars in Nephrology*, 41(2), 180–188. <https://doi.org/10.1016/j.semnephrol.2021.03.012>
- Malik, S., Bhanji, A., Abuleiss, H., Hamer, R., Shah, S. H., Rashad, R., Junglee, N., Waqar, S., & Ghouri, N. (2021). Effects of fasting on patients with chronic kidney disease during Ramadan and practical guidance for healthcare professionals. *Clinical Kidney Journal*, 14(6), 1524–1534. <https://doi.org/10.1093/ckj/sfab032>
- Malin, A. J., Lesseur, C., Busgang, S. A., Curtin, P., Wright, R. O., & Sanders, A. P. (2019). Fluoride exposure and kidney and liver function among adolescents in the United States: NHANES, 2013–2016. *Environment International*, 132(March), 105012. <https://doi.org/10.1016/j.envint.2019.105012>
- Mark, P. B., Stafford, L. K., Grams, M. E., Aalruz, H., Abd ElHafeez, S., Abdelgalil, A. A., Abdulkader, R. S., Abeywickrama, H. M., Abiodun, O. O., Abramov, D., Abrar, M. M., Abreu, L. G., Abubakar, B., Aburuz, S., Addo, I. Y., Adegboye, O. A., Adegboke, N. A., Adeyoluwa, T. E., Adnani, Q. E. S., Coresh, J. (2025). Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: A systematic analysis for the Global Burden of Disease Study 2023. *The Lancet*, 406(10518), 2461–2482. [https://doi.org/10.1016/S0140-6736\(25\)01853-7](https://doi.org/10.1016/S0140-6736(25)01853-7)
- Martín-del-Campo, F., Sotelo-Anaya, R., Castro-Mata, P. C., García-García, G., Gallardo-González, A. M., Gómez-Fregoso, J. A., Rodríguez-García, F. G., Luquin-Arellano, V. H., Abundis-Mora, G., Alcantar-Vallín, L., Medina-González, R., & Chavez-Iniguez, J. S. (2026a). Nutritional Parameters Associated With Hospital Mortality in Patients With Acute Kidney Injury. *Journal of Renal Nutrition*, 36(1), 49–57. <https://doi.org/10.1053/j.jrn.2025.07.003>
- Martín-del-Campo, F., Sotelo-Anaya, R., Castro-Mata, P. C., García-García, G., Gallardo-González, A. M., Gómez-Fregoso, J. A., Rodríguez-García, F. G., Luquin-Arellano, V. H., Abundis-Mora, G., Alcantar-Vallín, L., Medina-González, R., & Chavez-Iniguez, J. S. (2026b). Nutritional Parameters Associated With Hospital Mortality in Patients With Acute Kidney Injury. *Journal of Renal Nutrition*, 36(1), 49–57. <https://doi.org/10.1053/j.jrn.2025.07.003>
- McFarlane, C., Krishnasamy, R., Stanton, T., Savill, E., Snelson, M., Mihala, G., Morrison, M., Johnson, D. W., & Campbell, K. L. (2022). Diet Quality and Protein-Bound Uraemic Toxins: Investigation of Novel Risk Factors and the Role of Microbiome in Chronic Kidney Disease. *Journal of Renal Nutrition*, 32(5), 542–551. <https://doi.org/10.1053/j.jrn.2021.10.003>
- McFarlane, C., Ramos, C. I., Johnson, D. W., & Campbell, K. L. (2019). Prebiotic, Probiotic, and Synbiotic Supplementation in Chronic Kidney Disease: A Systematic Review and Meta-analysis. *Journal of Renal Nutrition*, 29(3), 209–220. <https://doi.org/10.1053/j.jrn.2018.08.008>
- Mehrotra, R. (2019). Advancing American Kidney Health: An Introduction. *Clinical Journal of the American Society of Nephrology*, 14(12). https://journals.lww.com/cjasn/Fulltext/2019/12000/Advancing_American_Kidney_Health_An_Introduction.17.aspx

References

- Melsom, T., Norvik, J. V., Enoksen, I. T., Stefansson, V., Mathisen, U. D., Fuskevåg, O. M., Jenssen, T. G., Solbu, M. D., & Eriksen, B. O. (2022). Sex Differences in Age-Related Loss of Kidney Function. *Journal of the American Society of Nephrology*, 33(10). https://journals.lww.com/jasn/Fulltext/2022/10000/Sex_Differences_in_Age_Related_Loss_of_Kidney.16.aspx
- Miskulin, D. C., Majchrzak, K., Tighiouart, H., Muther, R. S., Kapoian, T., Johnson, D. S., & Weiner, D. E. (2016). Ergocalciferol supplementation in hemodialysis patients with Vitamin D deficiency: A randomized clinical trial. *Journal of the American Society of Nephrology*, 27(6), 1801–1810. <https://doi.org/10.1681/ASN.2015040468>
- Mitch, W. E., & Remuzzi, G. (2016). Diets for patients with chronic kidney disease, should we reconsider? *BMC Nephrology*, 17(1), 1–8. <https://doi.org/10.1186/s12882-016-0283-x>
- Miwa, K., Tanaka, M., Okazaki, S., Furukado, S., Yagita, Y., Sakaguchi, M., Mochizuki, H., & Kitagawa, K. (2014). Chronic kidney disease is associated with dementia independent of cerebral small-vessel disease. *Neurology*, 82(12), 1051–1057.
- Mohammadi, M. A., Behrouz, V., Shahabi, A., & Abbas-Hashemi, S. A. (2025). The Association Between Dietary Inflammatory Index and Risk of Chronic Kidney Disease: An Updated Systematic Review and Dose–Response Meta-Analysis of Observational Studies. *Journal of Renal Nutrition*, 0(0). <https://doi.org/10.1053/j.jrn.2025.10.005>
- Moldovan, D., Kacso, I., Avram, L., Crisan, D., Condor, A., Bondor, C., Rusu, C., Potra, A., Tirinescu, D., Ticala, M., Maslyennikov, Y., Bărar, A., Urs, A., & Donca, V. (2025). Mental Health and Kidneys: The Interplay Between Cognitive Decline, Depression, and Kidney Dysfunction in Hospitalized Older Adults. *Journal of Clinical Medicine*, 14(12), 4120. <https://doi.org/10.3390/jcm14124120>
- Moludi, J., Qaisar, S. A., Kadhim, M. M., Ahmadi, Y., & Davari, M. (2022). Protective and therapeutic effectiveness of taurine supplementation plus low calorie diet on metabolic parameters and endothelial markers in patients with diabetes mellitus: A randomized, clinical trial. *Nutrition and Metabolism*, 19(1), 1–11. <https://doi.org/10.1186/s12986-022-00684-2>
- Moradi, H., & Said, H. M. (2016). Functional thiamine deficiency in end-stage renal disease: Malnutrition despite ample nutrients. *Kidney International*, 90(2), 252–254. <https://doi.org/10.1016/j.kint.2016.04.017>
- Muñoz-Castañeda, J. R., Pendón-Ruiz De Mier, M. V., Rodríguez, M., & Rodríguez-Ortiz, M. E. (2018). Magnesium replacement to protect cardiovascular and kidney damage? Lack of prospective clinical trials. *International Journal of Molecular Sciences*, 19(3), 1–19. <https://doi.org/10.3390/ijms19030664>
- Nanamatsu, A., de Araújo, L., LaFavers, K. A., & El-Achkar, T. M. (2024). Advances in uromodulin biology and potential clinical applications. *Nature Reviews. Nephrology*, 20(12), 806–821. <https://doi.org/10.1038/s41581-024-00881-7>
- Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., Bompont, S., Levin, A., & Jardine, M. J. (2019). SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis. *The Lancet Diabetes & Endocrinology*, 7(11), 845–854. [https://doi.org/10.1016/S2213-8587\(19\)30256-6](https://doi.org/10.1016/S2213-8587(19)30256-6)
- Nirumand, M. C., Hajjalyani, M., Rahimi, R., Farzaei, M. H., Zingue, S., Nabavi, S. M., & Bishayee, A. (2018). Dietary Plants for the Prevention and Management of Kidney Stones: Preclinical and Clinical Evidence and Molecular Mechanisms. *International Journal of Molecular Sciences*, 19(3), 765. <https://doi.org/10.3390/ijms19030765>

References

- Norris, T., Razieh, C., Yates, T., Zaccardi, F., Gillies, C. L., Chudasama, Y. V., Rowlands, A., Davies, M. J., McCann, G. P., Banerjee, A., Docherty, A. B., Openshaw, P. J. M., Baillie, J. K., Semple, M. G., Lawson, C. A., & Khunti, K. (2022). Admission Blood Glucose Level and Its Association With Cardiovascular and Renal Complications in Patients Hospitalized With COVID-19. *Diabetes Care*, 45(5), 1132–1140. <https://doi.org/10.2337/dc21-1709>
- Obeid, W., Hiremath, S., & Topf, J. M. (2022). Protein Restriction for CKD: Time to Move On. *Kidney360*, 3(9), 1611–1615. <https://doi.org/10.34067/kid.0001002022>
- Oliveira, M. W. S., Minotto, J. B., de Oliveira, M. R., Zanotto-Filho, A., Behr, G. A., Rocha, R. F., Moreira, J. C. F., & Klamt, F. (2010). Scavenging and antioxidant potential of physiological taurine concentrations against different reactive oxygen/nitrogen species. *Pharmacological Reports: PR*, 62(1), 185–193. [https://doi.org/10.1016/s1734-1140\(10\)70256-5](https://doi.org/10.1016/s1734-1140(10)70256-5)
- Ong, A. C. M., & Torra, R. (2022). Can ketogenic dietary interventions slow disease progression in ADPKD: What we know and what we don't. *Clinical Kidney Journal*, 15(6), 1034–1036. <https://doi.org/10.1093/ckj/sfac103>
- Ostadmohammadi, V., Soleimani, A., Bahmani, F., Aghadavod, E., Ramezani, R., Reiter, R. J., Mansournia, M. A., Banikazemi, Z., Soleimani, M., Zaroudi, M., & Asemi, Z. (2020). The Effects of Melatonin Supplementation on Parameters of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial. *Journal of Renal Nutrition*, 30(3), 242–250. <https://doi.org/10.1053/j.jrn.2019.08.003>
- Ostermann, M., Summers, J., Lei, K., Card, D., Harrington, D. J., Sherwood, R., Turner, C., Dalton, N., Peacock, J., & Bear, D. E. (2020). Micronutrients in critically ill patients with severe acute kidney injury – a prospective study. *Scientific Reports*, 10(1), 1–13. <https://doi.org/10.1038/s41598-020-58115-2>
- Panjeta, M., Tahirović, I., Sofić, E., Corić, J., & Dervišević, A. (2017). Interpretation of Erythropoietin and Haemoglobin Levels in Patients with Various Stages of Chronic Kidney Disease. *Journal of Medical Biochemistry*, 36(2), 145–152. <https://doi.org/10.1515/jomb-2017-0014>
- Persson, P., Fasching, A., Teerlink, T., Hansell, P., & Palm, F. (2014). L-citrulline, but not l-arginine, prevents diabetes mellitus-induced glomerular hyperfiltration and proteinuria in rat. *Hypertension*, 64(2), 323–329. <https://doi.org/10.1161/HYPERTENSIONAHA.114.03519>
- Peter, R. S., Nieters, A., Kräusslich, H. G., Brockmann, S. O., Göpel, S., Kindle, G., Merle, U., Steinacker, J. M., Rothenbacher, D., & Kern, W. V. (2022). Post-acute sequelae of covid-19 six to 12 months after infection: Population based study. *The BMJ*, 1–10. <https://doi.org/10.1136/bmj-2022-071050>
- Pierce, B. L., Tong, L., Dean, S., Argos, M., Jasmine, F., Rakibuz-Zaman, M., Sarwar, G., Islam, Md. T., Shahriar, H., Islam, T., Rahman, M., Yunus, Md., Lynch, V. J., Oglesbee, D., Graziano, J. H., Kibriya, M. G., Gamble, M. V., & Ahsan, H. (2019). A missense variant in FTCD is associated with arsenic metabolism and toxicity phenotypes in Bangladesh. *PLOS Genetics*, 15(3), e1007984.
- Potok, O. A., Katz, R., Bansal, N., Langlo, K. A., & Hallan, S. I. (2026). Using the Difference Between Estimated Glomerular Filtration Rate by Cystatin C and Creatinine to Improve Mortality Risk Prediction in Elderly Patients With CKD in the HUNT Study. *Kidney Medicine*, 8(1). <https://doi.org/10.1016/j.xkme.2025.101129>
- Pupim, L. B., Majchrzak, K. M., Flakoll, P. J., & Ikizler, T. A. (2006). Intradialytic Oral Nutrition Improves Protein Homeostasis in Chronic Hemodialysis Patients with Deranged Nutritional Status. *Journal of the American Society of Nephrology*, 17(11). https://journals.lww.com/jasn/Fulltext/2006/11000/Intradialytic_Oral_Nutrition_Improves_Protein.28.aspx

References

- Rakowski, D. A., Caillard, S., Agodoa, L. Y., & Abbott, K. C. (2006). Dementia as a predictor of mortality in dialysis patients. *Clinical Journal of the American Society of Nephrology : CJASN*, 1(5), 1000–1005. <https://doi.org/10.2215/CJN.00470705>
- Ramos, C. I., Armani, R. G., Canziani, M. E., Ribeiro Dolenga, C. J., Nakao, L. S., Campbell, K. L., & Cuppari, L. (2020a). Bowel Habits and the Association With Uremic Toxins in Non–Dialysis-Dependent Chronic Kidney Disease Patients. *Journal of Renal Nutrition*, 30(1), 31–35. <https://doi.org/10.1053/j.jrn.2019.02.004>
- Ramos, C. I., Armani, R. G., Canziani, M. E., Ribeiro Dolenga, C. J., Nakao, L. S., Campbell, K. L., & Cuppari, L. (2020b). Bowel Habits and the Association With Uremic Toxins in Non–Dialysis-Dependent Chronic Kidney Disease Patients. *Journal of Renal Nutrition*, 30(1), 31–35. <https://doi.org/10.1053/j.jrn.2019.02.004>
- Ramspek, C. L., Evans, M., Wanner, C., Drechsler, C., Chesnaye, N. C., Szymczak, M., Krajewska, M., Torino, C., Porto, G., Hayward, S., Caskey, F., Dekker, F. W., Jager, K. J., & van Diepen, M. (2021). Kidney Failure Prediction Models: A Comprehensive External Validation Study in Patients with Advanced CKD. *Journal of the American Society of Nephrology : JASN*, 32(5), 1174–1186. <https://doi.org/10.1681/ASN.2020071077>
- Rapa, S. F., Di Iorio, B. R., Campiglia, P., Heidland, A., & Marzocco, S. (2020). Inflammation and oxidative stress in chronic kidney disease—Potential therapeutic role of minerals, vitamins and plant-derived metabolites. *International Journal of Molecular Sciences*, 21(1). <https://doi.org/10.3390/ijms21010263>
- Raphael, K. L., Greene, T., Wei, G., Bullshoe, T., Tuttle, K., Cheung, A. K., & Beddhu, S. (2020). Sodium bicarbonate supplementation and urinary TGF-β1 in nonacidotic diabetic kidney disease a randomized, controlled trial. *Clinical Journal of the American Society of Nephrology*, 15(2), 200–208. <https://doi.org/10.2215/CJN.06600619>
- Reddy, S. T., Wang, C.-Y., Sakhaee, K., Brinkley, L., & Pak, C. Y. C. (2002). Effect of low-carbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism. *American Journal of Kidney Diseases*, 40(2), 265–274. <https://doi.org/10.1053/ajkd.2002.34504>
- Reese, J. T., Blau, H., Casiraghi, E., Bergquist, T., Loomba, J. J., Callahan, T. J., Laraway, B., Antonescu, C., Coleman, B., Gargano, M., Wilkins, K. J., Cappelletti, L., Fontana, T., Ammar, N., Antony, B., Murali, T. M., Caufield, J. H., Karlebach, G., McMurry, J. A., ... Divers, J. (2023). Generalisable long COVID subtypes: Findings from the NIH N3C and RECOVER programmes. *eBioMedicine*, 87, 1–17. <https://doi.org/10.1016/j.ebiom.2022.104413>
- Roozbeh, J., Shahriyari, B., Akmal, M., Vessal, G., Pakfetrat, M., Jalali, G. A. R., Afshariani, R., Hasheminasab, M., & Ghahramani, N. (2011). Comparative effects of silymarin and vitamin E supplementation on oxidative stress markers, and hemoglobin levels among patients on hemodialysis. *Renal Failure*, 33(2), 118–123. <https://doi.org/10.3109/0886022X.2010.541579>
- Rossi, M., Johnson, D. W., & Campbell, K. L. (2015). The Kidney–Gut Axis: Implications for Nutrition Care. *Journal of Renal Nutrition*, 25(5), 399–403. <https://doi.org/10.1053/j.jrn.2015.01.017>
- Roumeliotis, S., Mallamaci, F., & Zoccali, C. (2020). Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update. *Journal of Clinical Medicine*, 9(8), 2359. <https://doi.org/10.3390/jcm9082359>
- Sabaghian, T., Kharazmi, A. B., Ansari, A., Omid, F., Kazemi, S. N., Hajikhani, B., Vaziri-Harami, R., Tajbakhsh, A., Omid, S., Haddadi, S., Shahidi Bonjar, A. H., Nasiri, M. J., & Mirsaeidi, M. (2022). COVID-19 and Acute Kidney Injury: A Systematic Review. *Frontiers in Medicine*, 9(April), 1–9. <https://doi.org/10.3389/fmed.2022.705908>
- Sabatino, A., Cuppari, L., Stenvinkel, P., Lindholm, B., & Avesani, C. M. (2020). Sarcopenia in chronic kidney disease: What have we learned so far? *Journal of Nephrology*, (0123456789). <https://doi.org/10.1007/s40620-020-00840-y>
- Saglimbene, V. M., Wong, G., van Zwielen, A., Palmer, S. C., Ruospo, M., Natale, P., Campbell, K., Teixeira-Pinto, A., Craig, J. C., & Strippoli, G. F. M. (2020). Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials. *Clinical Nutrition*, 39(2), 358–368. <https://doi.org/10.1016/j.clnu.2019.02.041>

References

- Saito, J., Matsuzawa, Y., Ito, H., Omura, M., Ito, Y., Yoshimura, K., Yajima, Y., Kino, T., & Nishikawa, T. (2010). The alkalizer citrate reduces serum uric Acid levels and improves renal function in hyperuricemic patients treated with the xanthine oxidase inhibitor allopurinol. *Endocrine Research*, 35(4), 145–154. <https://doi.org/10.3109/07435800.2010.497178>
- Sällström, J., Carlström, M., Olerud, J., Fredholm, B. B., Kouzmine, M., Sandler, S., & Persson, A. E. G. (2010). High-protein-induced glomerular hyperfiltration is independent of the tubuloglomerular feedback mechanism and nitric oxide synthases. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, 299(5), 1263–1268. <https://doi.org/10.1152/ajpregu.00649.2009>
- Self, W. H., Shotwell, M. S., Gibbs, K. W., de Wit, M., Files, D. C., Harkins, M., Hudock, K. M., Merck, L. H., Moskowitz, A., Apodaca, K. D., Barksdale, A., Safdar, B., Javaheri, A., Sturek, J. M., Schrager, H., Iovine, N., Tiffany, B., Douglas, I. S., Levitt, J., ... Investigators, A.-4 H. T. (2023). Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor–Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials. *JAMA*, 329(14), 1170–1182. <https://doi.org/10.1001/jama.2023.3546>
- Seliger, S. L., Siscovick, D. S., Stehman-Breen, C. O., Gillen, D. L., Fitzpatrick, A., Bleyer, A., & Kuller, L. H. (2004). Moderate renal impairment and risk of dementia among older adults: The cardiovascular health cognition study. *Journal of the American Society of Nephrology*, 15(7), 1904–1911. <https://doi.org/10.1097/01.ASN.0000131529.60019.FA>
- Sengupta, P., Biswas, S., & Roy, T. (2022). Comparative Study to Evaluate the Effect of Low-Protein Diet Supplementation with Taurine and N-Acetylcysteine, N-Acetylcysteine and Pyridoxamine Dihydrochloride in Preventing the Progression of Chronic Renal Failure in Patients with Non-Diabetic Kidney D. *The Journal of the Association of Physicians of India*, 70(5), 11–12.
- Sharma, B., & Yadav, D. K. (2023). L-Carnitine and Chronic Kidney Disease: A Comprehensive Review on Nutrition and Health Perspectives. *Journal of Personalized Medicine*, 13(2). <https://doi.org/10.3390/jpm13020298>
- Shi, R., Mancuso, J., Borick, E., Sheiber, J., Zhu, X., Joshi, S., & Shah, A. D. (2025). Impact of Plant-Based Diets on Blood Pressure in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. *Journal of Renal Nutrition*, 0(0). <https://doi.org/10.1053/j.jrn.2025.10.014>
- Shi, Y., Duan, H., Liu, J., Shi, X., Zhao, M., Fang, Y., & Zhang, Y. (2026). Prevalence and Prognostic Significance of Malnutrition in Critically Ill Patients With Acute Kidney Injury. *Journal of Renal Nutrition*, 36(1), 58–69. <https://doi.org/10.1053/j.jrn.2025.09.006>
- Shirbhate, E., Pandey, J., Patel, V. K., Kamal, M., Jawaid, T., & Gorain, B. (2021). Understanding the role of ACE - 2 receptor in pathogenesis of COVID - 19 disease: A potential approach for therapeutic intervention. *Pharmacological Reports*, 73(6), 1539–1550. <https://doi.org/10.1007/s43440-021-00303-6>
- Song, B. C., Joo, N.-S., Aldini, G., & Yeum, K.-J. (2014). Biological functions of histidine-dipeptides and metabolic syndrome. *Nutrition Research and Practice*, 8(1), 3–10. <https://doi.org/10.4162/nrp.2014.8.1.3>
- Srivastava, A., Kaze, A. D., McMullan, C. J., Isakova, T., & Waikar, S. S. (2018). Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD. *American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation*, 71(3), 362–370. <https://doi.org/10.1053/j.ajkd.2017.08.017>

References

- Steiber, A. L., & Kopple, J. D. (2011). Vitamin Status and Needs for People with Stages 3-5 Chronic Kidney Disease. *Journal of Renal Nutrition*, 21(5), 355–368. <https://doi.org/10.1053/j.jrn.2010.12.004>
- Su, Y., Yuan, D., Chen, D. G., Ng, R. H., Wang, K., Choi, J., Li, S., Hong, S., Zhang, R., Xie, J., Kornilov, S. A., Scherler, K., Pavlovitch-Bedzyk, A. J., Dong, S., Lausted, C., Lee, I., Fallen, S., Dai, C. L., Baloni, P., ... Heath, J. R. (2022). Multiple early factors anticipate post-acute COVID-19 sequelae. *Cell*, 185(5), 881–895.e20. <https://doi.org/10.1016/j.cell.2022.01.014>
- Suliman, M. E., Bárány, P., Filho, J. C. D., Lindholm, B., & Bergström, J. (2002). Accumulation of taurine in patients with renal failure. *Nephrology Dialysis Transplantation*, 17(3), 528–529. <https://doi.org/10.1093/ndt/17.3.528>
- Suzuki, H., & Kondo, K. (2012). Chronic kidney disease in postmenopausal women. *Hypertension Research*, 35(2), 142–147. <https://doi.org/10.1038/hr.2011.155>
- Taes, Y. E. C., Delanghe, J. R., Wuyts, B., van de Voorde, J., & Lameire, N. H. (2003). Creatine supplementation does not affect kidney function in an animal model with pre-existing renal failure. *Nephrology Dialysis Transplantation*, 18(2), 258–264. <https://doi.org/10.1093/ndt/18.2.258>
- Takahashi, A. (2022). Role of Zinc and Copper in Erythropoiesis in Patients on Hemodialysis. *Journal of Renal Nutrition*, 32(6), 650–657. <https://doi.org/10.1053/j.jrn.2022.02.007>
- Tanaka, S., & Okusa, M. D. (2020). Crosstalk between the nervous system and the kidney. *Kidney International*, 97(3), 466–476. <https://doi.org/10.1016/j.kint.2019.10.032>
- Thalacker-Mercer, A. E., & Gheller, M. E. (2020). Benefits and adverse effects of histidine supplementation. *Journal of Nutrition*, 150(8), 2588S–2592S. <https://doi.org/10.1093/jn/nxaa229>
- Thongprayoon, C., Krambeck, A. E., & Rule, A. D. (2020). Determining the true burden of kidney stone disease. *Nature Reviews Nephrology*, 16(12), 736–746. <https://doi.org/10.1038/s41581-020-0320-7>
- Tirosh, A., Golan, R., Harman-Boehm, I., Henkin, Y., Schwarzfuchs, D., Rudich, A., Kovsan, J., Fiedler, G. M., Blüher, M., Stumvoll, M., Thiery, J., Stampfer, M. J., & Shai, I. (2013). Renal function following three distinct weight loss dietary strategies during 2 years of a randomized controlled trial. *Diabetes Care*, 36(8), 2225–2232. <https://doi.org/10.2337/dc12-1846>
- Tong, J., Li, C., Hu, J., Teng, Y., Zhou, Y., & Tao, M. (2022). Association of sleep characteristics with renal function in menopausal women without recognized chronic kidney disease. *Frontiers in Psychiatry*, 13(November), 1–10. <https://doi.org/10.3389/fpsy.2022.1024245>
- Torres, J. A., Kruger, S. L., Broderick, C., Amarikhagva, T., Agrawal, S., Dodam, J. R., Mrug, M., Lyons, L. A., & Weimbs, T. (2019). Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease. *Cell Metabolism*, 30(6), 1007–1023.e5. <https://doi.org/10.1016/j.cmet.2019.09.012>
- Tsai, C. W., Lin, S. Y., Kuo, C. C., & Huang, C. C. (2017). Serum uric acid and progression of kidney disease: A longitudinal analysis and mini-review. *PLoS ONE*, 12(1), 1–16. <https://doi.org/10.1371/journal.pone.0170393>
- Tsai, C. W., Ting, I. W., Yeh, H. C., & Kuo, C. C. (2017). Longitudinal change in estimated GFR among CKD patients: A 10-year follow-up study of an integrated kidney disease care program in Taiwan. *PLoS ONE*, 12(4). <https://doi.org/10.1371/journal.pone.0173843>

References

- Tungsanga, S., Okpechi, I. G., Bianchi, M. E. V., Chaturvedi, S., Collister, D., Crowshoe, H., Rodriguez de Sosa, G. M., Galadanci, H. A., Hedin, E., Ibrahim, K. S., Jain, A. K., Noronha, I. L., Erickson, R. L., Hughes, J. T., Komenda, P., Kulvichit, W., Pecoits-Filho, R., Raphael, K. L., Shah, V. O., ... Bello, A. K. (2026). Global landscape of kidney health across Indigenous populations. *Nature Reviews Nephrology*, 22(2), 99–121. <https://doi.org/10.1038/s41581-025-01016-2>
- Ume, A. C., Wenegieme, T. Y., Adams, D. N., Adesina, S. E., & Williams, C. R. (2023). Zinc Deficiency: A Potential Hidden Driver of the Detrimental Cycle of Chronic Kidney Disease and Hypertension. *Kidney360*, 4(3), 398–404. <https://doi.org/10.34067/KID.0007812021>
- van de Wal-Visscher, E. R., Kooman, J. P., & van der Sande, F. M. (2018). Magnesium in Chronic Kidney Disease: Should We Care? *Blood Purification*, 45(1–3), 173–178. <https://doi.org/10.1159/000485212>
- van der Veen, Y., Post, A., Kremer, D., Koops, C. A., Marsman, E., Appeldoorn, T. Y. J., Touw, D. J., Westervhuis, R., Heiner-Fokkema, M. R., Franssen, C. F. M., Wallimann, T., & Bakker, S. J. L. (2021). Chronic dialysis patients are depleted of creatine: Review and rationale for intradialytic creatine supplementation. *Nutrients*, 13(8). <https://doi.org/10.3390/nu13082709>
- Varga, Z., Sabzwari, S. rafay ali, & Vargova, V. (2017). Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue. *Cureus*, 9(4). <https://doi.org/10.7759/cureus.1144>
- Vera-Aviles, M., Vantana, E., Kardinari, E., Koh, N., & Latunde-Dada, G. (2018). Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease. *Pharmaceuticals*, 11(4), 111. <https://doi.org/10.3390/ph11040111>
- Wallimann, T., Riek, U., & Möddel, M. (2017). Intradialytic creatine supplementation: A scientific rationale for improving the health and quality of life of dialysis patients. *Medical Hypotheses*, 99, 1–14. <https://doi.org/10.1016/j.mehy.2016.12.002>
- Watanabe, M., Suliman, M. E., Qureshi, A. R., Garcia-Lopez, E., Bárány, P., Heimbürger, O., Stenvinkel, P., & Lindholm, B. (2008). Consequences of low plasma histidine in chronic kidney disease patients: Associations with inflammation, oxidative stress, and mortality. *American Journal of Clinical Nutrition*, 87(6), 1860–1866. <https://doi.org/10.1093/ajcn/87.6.1860>
- Wesson, D. E., Simoni, J., Broglio, K., & Sheather, S. (2011). Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone. *American Journal of Physiology - Renal Physiology*, 300(4), 830–837. <https://doi.org/10.1152/ajprenal.00587.2010>
- Wetzels, J. F. M., Kiemeny, L. A. L. M., Swinkels, D. W., Willems, H. L., & Heijer, M. D. (2007). Age- and gender-specific reference values of estimated GFR in Caucasians: The Nijmegen Biomedical Study. *Kidney International*, 72(5), 632–637. <https://doi.org/10.1038/sj.ki.5002374>
- Witasp, A., Luttrupp, K., Qureshi, A. R., Barany, P., Heimbürger, O., Wennberg, L., Ekström, T. J., Shiels, P. G., Stenvinkel, P., & Nordfors, L. (2022). Longitudinal genome-wide DNA methylation changes in response to kidney failure replacement therapy. *Scientific Reports*, 12(1), 1–14. <https://doi.org/10.1038/s41598-021-04321-5>

References

- Wright, M., Southcott, E., MacLaughlin, H., & Wineberg, S. (2019). Clinical practice guideline on undernutrition in chronic kidney disease. *BMC Nephrology*, 20(1), 1–10. <https://doi.org/10.1186/s12882-019-1530-8>
- Yamada, S., & Inaba, M. (2021). Potassium metabolism and management in patients with ckd. *Nutrients*, 13(6), 1–19. <https://doi.org/10.3390/nu13061751>
- Yen, C.-L., Fan, P.-C., Kuo, G., Chen, C.-Y., Cheng, Y.-L., Hsu, H.-H., Tian, Y.-C., Chatrenet, A., Piccoli, G. B., & Chang, C.-H. (2021). Supplemented Low-Protein Diet May Delay the Need for Preemptive Kidney Transplantation: A Nationwide Population-Based Cohort Study. *Nutrients*, 13(9). <https://doi.org/10.3390/nu13093002>
- Yuen, N. K., Ananthakrishnan, S., & Campbell, M. J. (2016). Hyperparathyroidism of Renal Disease. *The Permanente Journal*, 20(3), 78–83. <https://doi.org/10.7812/TPP/15-127>
- Zang, H., Mathew, R. O., & Cui, T. (2020). The Dark Side of Nrf2 in the Heart. *Frontiers in Physiology*, 11(July), 1–8. <https://doi.org/10.3389/fphys.2020.00722>
- Zhang, H. W., Lin, Z. X., Xu, C., Leung, C., & Chan, L. S. (2014). Astragalus (a traditional Chinese medicine) for treating chronic kidney disease. *Cochrane Database of Systematic Reviews*, 2014(10). <https://doi.org/10.1002/14651858.CD008369.pub2>
- Zhang, H., Zang, C., Xu, Z., Zhang, Yongkang, Xu, J., Bian, J., Morozuk, D., Khullar, D., Zhang, Yiye, Nordvig, A. S., Schenck, E. J., Shenkman, E. A., Rothman, R. L., Block, J. P., Lyman, K., Weiner, M. G., Carton, T. W., Wang, F., & Kaushal, R. (2023). Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. *Nature Medicine*, 29(1), 226–235. <https://doi.org/10.1038/s41591-022-02116-3>
- Zhang, Z., He, P., Liu, M., Zhou, C., Liu, C., Li, H., Zhang, Y., Li, Q., Ye, Z., Wu, Q., Wang, G., Liang, M., & Qin, X. (2021). Association of Depressive Symptoms with Rapid Kidney Function Decline in Adults with Normal Kidney Function. *Clin J Am Soc Nephrol.*, 16(9), 1–9. <https://doi.org/10.2215/CJN.18441120>
- Zhou, C., Zhang, Q., Lu, L., Wang, J., Liu, D., & Liu, Z. (2021). Metabolomic Profiling of Amino Acids in Human Plasma Distinguishes Diabetic Kidney Disease From Type 2 Diabetes Mellitus. *Frontiers in Medicine*, 8(November), 1–11. <https://doi.org/10.3389/fmed.2021.765873>
- Zobel, E. H., von Scholten, B. J., Reinhard, H., Persson, F., Teerlink, T., Hansen, T. W., Parving, H. H., Jacobsen, P. K., & Rossing, P. (2017). Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. *Cardiovascular Diabetology*, 16(1), 1–9. <https://doi.org/10.1186/s12933-017-0569-8>
- Zoccali, C., Vanholder, R., Massy, Z. A., Ortiz, A., Sarafidis, P., Dekker, F. W., Fliser, D., Fouque, D., Heine, G. H., Jager, K. J., Kanbay, M., Mallamaci, F., Parati, G., Rossignol, P., Wiecek, A., & London, G. (2017). The systemic nature of CKD. *Nature Reviews Nephrology*, 13(6), 344–358. <https://doi.org/10.1038/nrneph.2017.52>